♦ Session A ♦ Session B ♦ Session C ♦
General Poster Session A: Prostate Cancer
Abstract # 1 : Gleason upgrading with time in a large, active surveillance cohort with long-term follow-up. ( A1 )
D. Andrew Loblaw - Sunnybrook Health Sciences Centre (First author: Suneil Jain - Sunnybrook Health Sciences Centre )
Abstract # 2 : Associations between single nucleotide polymorphisms (SNPs) in inflammation-related genes and quality of life after radiation therapy (RT) for prostate cancer. ( A2 )
Jonathan D. Schoenfeld - Harvard Radiation Oncology Program
Abstract # 3 : High-risk prostate cancer treated with pelvic radiotherapy and 36 versus 18 months of androgen blockade: Results of a phase III randomized study. ( A3 )
Abdenour Nabid Centre Hospitalier Universitaire de Sherbrooke
Abstract # 4 : Phase III results of adjuvant radiotherapy (RT) versus wait-and-see (WS) in patients with pT3 prostate cancer following radical prostatectomy (RP)(ARO 96-02/AUO AP 09/95): Ten years follow-up. ( A4 )
Thomas Wiegel - University of Ulm
Abstract # 5 : Updated interim analysis (IA) of COU-AA-302, a randomized phase III study of abiraterone acetate (AA) in patients (pts) with metastatic castration-resistant prostate cancer (mCRPC) without prior chemotherapy. ( A5 )
Dana E. Rathkopf - Memorial Sloan-Kettering Cancer Center
Abstract # 6 : Impact of on-study corticosteroid use on efficacy and safety in the phase III AFFIRM study of enzalutamide (ENZA), an androgen receptor inhibitor. ( A6 )
Howard I. Scher - Sidney Kimmel Center for Prostate and Urologic Cancers, Memorial Sloan-Kettering Cancer Center
Abstract # 7 : ARN-509 in men with high-risk nonmetastatic castration-resistant prostate cancer (CRPC). ( A7 )
Matthew Raymond Smith - Massachusetts General Hospital Cancer Center
Abstract #LBA8 : Overall survival (OS) and safety of dasatinib/docetaxel versus docetaxel in patients with metastatic castration-resistant prostate cancer (mCRPC): Results from the randomized phase III READY trial. ( A8 )
John Araujo - The University of Texas MD Anderson Cancer Center
Abstract # 9 : Long-term efficacy of stereotactic body radiotherapy for localized prostate cancer: A multi-institutional pooled analysis. ( A9 )
Patrick Kupelian - University of California, Los Angeles
Abstract # 10 : Long-term survival of subjects in the prostate cancer prevention trial. ( B1 )
Phyllis J. Goodman - SWOG Statistical Center
Abstract # 11 : Updated analysis of radium-223 dichloride (Ra-223) impact on skeletal-related events (SRE) in patients with castration-resistant prostate cancer (CRPC) and bone metastases from the phase III randomized trial (ALSYMPCA). ( B2 )
Nicholas J. Vogelzang - Comprehensive Cancer Centers of Nevada
Abstract # 12 : Identification of men with a genetic predisposition to prostate cancer: Targeted screening in men at higher genetic risk and controls—The impact study. ( B3 )
Ros A. Eeles - The Institute of Cancer Research and The Royal Marsden NHS Foundation Trust
Abstract # 13 : Aflibercept versus placebo in combination with docetaxel/prednisone for first-line treatment of men with metastatic castration-resistant prostate cancer (mCRPC): Results from the multinational phase III trial (VENICE). ( B4 )
Ian Tannock - Princess Margaret Hospital and University of Toronto
Abstract # 14 : Exploratory analysis of the visceral disease (VD) patient subset in COU-AA-301, a phase III study of abiraterone acetate (AA) in metastatic castration-resistant prostate cancer (mCRPC). ( B5 )
Oscar B. Goodman - Comprehensive Cancer Centers of Nevada
Abstract # 15 : Does the diagnosing urologist influence choice of initial active treatment versus observation in older men with favorable prostate cancer? ( B6 )
Karen Elizabeth Hoffman - The University of Texas MD Anderson Cancer Center
Abstract # 16 : Improved outcomes in elderly patients with metastatic castration-resistant prostate cancer (mCRPC) treated with the androgen receptor inhibitor enzalutamide: Results from the phase III affirm trial. ( B7 )
Cora N. Sternberg - San Camillo and Forlanini Hospital
Abstract # 17 : Effect of enzalutamide on health-related quality of life (HRQoL) in men with metastatic castration-resistant prostate cancer (mCRPC) following docetaxel-based therapy: Results from the AFFIRM study. ( B8 )
Kurt Miller - Charité-Universitätsmedizin Berlin
Abstract # 18 : Enzalutamide monotherapy: Phase II study results in patients with hormone-naive prostate cancer. ( B9 )
Bertrand Tombal - Université Catholique de Louvain, Cliniques Universitaires Saint-Luc
Abstract # 19 : Pain analysis from the phase III randomized ALSYMPCA study with radium-223 dichloride (Ra-223) in patients with castration-resistant prostate cancer (CRPC) with bone metastases. ( B10 )
Sten Nilsson - Karolinska University Hospital
Abstract # 20 : Long-term responders to enzalutamide (ENZA) during the phase III AFFIRM trial: Baseline characteristics and efficacy outcomes. ( B11 )
Mark T. Fleming - Virginia Oncology Associates
Abstract # 21 : Effect of dutasteride on tumor proliferation during the regrowth phase of intermittent androgen ablation therapy in men with advanced prostate cancer. ( B12 )
Daniel H. Shevrin - NorthShore University HealthSystem
Abstract # 22 : Prognostic value of serum androgens, by ultrasensitive assay, in metastatic castration-resistant prostate cancer (mCRPC): Phase III trial data. ( B13 )
Charles J. Ryan - University of California, San Francisco
Abstract # 23 : Paradoxical significance of endorectal MRI (erMRI) response to neoadjuvant chemotherapy in patients with high-risk localized prostate cancer (HRLPC). ( B14 )
Matt D. Galsky - Division of Hematology and Medical Oncology, The Tisch Cancer Institute, Mount Sinai School of Medicine
Abstract # 24 : A model for predicting overall survival in men with metastatic castrate-resistant prostate cancer (CRPC) for whom first-line chemotherapy failed. ( B15 )
Susan Halabi - Duke University Medical Center
Abstract # 25 : Impact of the USPSTF D recommendation: Early assessment of referrals for elevated PSA and prostate biopsies in a LUGPA following statement revision. ( B16 )
Kathleen F. McGinley - University of Medicine and Dentistry of New Jersey - School of Osteopathic Medicine
Abstract # 26 : Identification of prognostic groups in patients with hormone-sensitive metastatic prostate cancer at the present time: An analysis of the GETUG 15 phase III trial. ( B17 )
Gwenaelle Gravis - Department of Medical Oncology, Institut Paoli Calmettes
Abstract # 27 : Efficacy and safety of zoledronic acid in men with castration-sensitive prostate cancer and bone metastases: Results of CALGB 90202 (Alliance). ( B18 )
Matthew Raymond Smith - Massachusetts General Hospital Cancer Center
Abstract # 28 : The effect of therapeutic anticoagulation on overall survival (OS) in men receiving docetaxel chemotherapy for metastatic castration-resistant prostate cancer (mCRPC). ( C1 )
Caroline F. Pratz - Johns Hopkins Sidney Kimmel Comprehensive Cancer Center
Abstract # 29 : Effect of germ-line BRCA mutations in biochemical relapse and survival after treatment for localized prostate cancer. ( C2 )
Elena Castro - The Institute of Cancer Research / Prostate Cancer Research Unit. Spanish National Cancer Research Centre
Abstract # 30 : Real-world experience with sipuleucel-T in patients (pts) with metastatic castration-resistant prostate cancer (mCRPC) who received prior docetaxel (D): Data from PROCEED.^ ( C3 )
A. Oliver Sartor - Tulane Cancer Center
Abstract # 31 : Phase I trial of zirconium 89 (Zr89) radiolabeled J591 in metastatic castration-resistant prostate cancer (mCRPC). ( C4 )
Michael J. Morris - Memorial Sloan-Kettering Cancer Center
Abstract # 33 : Characterization of patients who present with de novo metastatic prostate cancer: Single-institution database analysis. ( C6 )
Jessica Strock - Dana-Farber Cancer Institute
Abstract # 34 : Randomized phase II trial evaluating the optimal sequencing of sipuleucel-T and androgen-deprivation therapy (ADT) in patients (pts) with biochemically recurrent prostate cancer (BRPC). ( C7 )
Emmanuel S. Antonarakis - Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins University
Abstract # 35 : A multi-institutional clinical trial of rectal dose reduction via injected polyethylene-glycol hydrogel during IMRT for prostate cancer: Analysis of dosimetric outcomes. ( C8 )
Danny Y. Song - Johns Hopkins School of Medicine
Abstract # 36 : Validation of a genomic classifier that predicts metastatic disease progression in men with high-risk pathologic features postprostatectomy. ( C9 )
Mercedeh Ghadessi - GenomeDx Biosciences Inc.
Abstract # 37 : Adjuvant versus neoadjuvant androgen deprivation with radiation therapy for prostate cancer: Does sequencing matter? ( C10 )
Michael A. Weller - Cleveland Clinic
Abstract # 38 : Randomized phase II trial of docetaxel (Doc) and prednisone (Pred) with or without AZD2171 (cediranib), in chemotherapy-naive, metastatic castrate-resistant prostate cancer (mCRPC) (NCI 7451). ( C11 )
Elisabeth I. Heath - Karmanos Cancer Institute
Abstract # 39 : Changing trends in pelvic lymphadenectomy in radical prostatectomy with the advent of robotic surgery. ( C12 )
William Sohn - University of California, Irvine
Abstract # 40 : Changes in circulating tumor cells (CTC) and markers of inflammation after sipuleucel-T treatment. ( C13 )
Mehmet Hepgur - University of Southern California, Norris Comprehensive Cancer Center
Abstract # 41 : First-in-human study of AMG 208, an oral MET inhibitor, in adult patients (pts) with advanced solid tumors. ( C14 )
David S. Hong - The University of Texas MD Anderson Cancer Center
Abstract # 42 : Comparision of the risk of cardiovascular events and death in patients treated with degarelix compared with LHRH agonists. ( C15 )
Peter C. Albertsen - University of Connecticut Health Center
Abstract # 43 : The molecular relationship among concurrent prostate cancer foci. ( C16 )
David James VanderWeele - University of Chicago
Abstract # 44 : The initial biopsy Gleason score as a predictive marker for docetaxel survival benefit in patients with prostate cancer: Data from the TAX 327 study. ( C17 )
Robert van Soest - Erasmus University Medical Center
Abstract # 45 : Prostate-specific mRNA detection in whole blood as an analytically validated prognostic biomarker for patients with castration-resistant prostate cancer (CRPC). ( C18 )
Daniel Costin Danila - Memorial Sloan-Kettering Cancer Center
Abstract # 47 : Prognostic utility of CCP score in men with prostate cancer after primary external beam radiation therapy. ( D2 )
Stephen J. Freedland - Duke University Medical Center and Durham VA Medical Center
Abstract # 48 : ARN-509 in men with metastatic castration-resistant prostate cancer (mCRPC). ( D3 )
Dana E. Rathkopf - Sidney Kimmel Center for Prostate and Urologic Cancers, Memorial Sloan-Kettering Cancer Center
Abstract # 49 : Mortality following hip fractures in men with prostate cancer. ( D4 )
Mieke Van Hemelrijck - King's College London
Abstract # 50 : PSA-detected prostate cancer in the United States: A population-based study of 70,345 men with AJCC stage T1cN0M0 disease. ( D5 )
Hong Zhang - University of Rochester Medical Center
Abstract # 51 : A gene expression signature to predicit overall, prostate cancer, and non–prostate cancer survival. ( D6 )
Chunde Li - Department of Clinical Oncology, Karolinska University Hospital
Abstract # 52 : Validation of a genomic classifier that predicts metastatic disease progression in men with biochemical recurrence post radical prostatectomy. ( D7 )
Ashley E. Ross - Department of Urology, Johns Hopkins Medical Institutions
Abstract # 53 : Nomograms to predict late urinary toxicity after prostate cancer radiotherapy. ( D8 )
Romain Mathieu - CHU pontchaillou
Abstract # 54 : Evaluation of the UCSF cancer of the prostate risk assessment for prediction of biochemical recurrence (CAPRA) to predict which patients need dose escalation in intermediate-risk disease. ( D9 )
Daniel Taussky - Department of Radiation Oncology, Centre Hospitalier de l'Université de Montréal, Montreal University
Abstract # 55 : Multidisciplinary care and management of very low-risk prostate cancer. ( D10 )
Ayal A. Aizer - Harvard Radiation Oncology Program
Abstract # 56 : Image guidance for post-prostatectomy radiotherapy: Are we missing the mark? ( D11 )
Noah S. Kalman - Duke University Medical Center
Abstract # 57 : Effect of PSA-tricom, a pox-viral vaccine in prostate cancer (PCa), on tumor growth rates within 80 days after initiation in nonmetastatic PCa. ( D12 )
James L. Gulley - Laboratory of Tumor Immunology and Biology, Medical Oncology Branch, National Cancer Institute
Abstract # 58 : Modulation of soluble c-Met, bone turnover markers, angiogenic factors, and c-Met in men with mCRPC treated with cabozantinib. ( D13 )
Paul G. Corn - The University of Texas MD Anderson Cancer Center
Abstract # 59 : A phase I/II study of safety and efficacy of orteronel (TAK-700), an oral, investigational, nonsteroidal 17,20-lyase inhibitor, with docetaxel and prednisone (DP) in metastatic castration-resistant prostate cancer (mCRPC): Updated phase II results. ( D14 )
Daniel Petrylak - Columbia University Medical Center
Abstract # 60 : A genomic classifier independently prognostic of prostate cancer death in a high-risk surgical cohort. ( D15 )
Matthew R. Cooperberg - University of California, San Francisco
Abstract # 61 : Dissecting the therapeutic effects of anti-CTLA-4 and ADT in a murine hormone-sensitive prostate cancer. ( D16 )
Sumit Kumar Subudhi - Memorial Sloan-Kettering Cancer Center
Abstract # 62 : Evaluation of PTEN status in circulating tumor cells (CTCs) and matched tumor tissue from patients with castrate-resistant prostate cancer (CRPC). ( D17 )
Elizabeth Punnoose - Genentech
Abstract # 63 : Enzalutamide in combination with docetaxel in men with prostate cancer (PC): Preliminary results from a phase I study. ( D18 )
Mark T. Fleming - Virginia Oncology Associates
Abstract # 64 : Evaluating the hypothalamic-pituitary-adrenal axis (HPAA) in men receiving ketoconazole for castrate-resistant prostate cancer (CRPC). ( E1 )
Rahul Raj Aggarwal - University of California, San Francisco
Abstract # 65 : ODM-201, a new generation androgen receptor inhibitor for castration-resistant prostate cancer: Preclinical and phase I data.^ ( E2 )
Karim Fizazi - Department of Medical Oncology, Institut Gustave Roussy
Abstract # 66 : Association of radical prostate cancer therapy with a survival benefit in the older man. ( E3 )
Paul Cathcart - University College Hospital London
Abstract # 67 : Development and validation of a mutivariate model combining cell cycle progression score with CAPRA to predict prostate cancer mortality in a conservatively managed cohort. ( E4 )
Michael K. Brawer - Myriad Genetic and Laboratories, Inc.
Abstract # 68 : Degarelix versus LHRH agonists: Differential skeletal and urinary tract outcomes from an analysis of six comparative randomized clinical trials. ( E5 )
E. David Crawford - University of Colorado Cancer Center
Abstract # 69 : Sentinel lymph node in prostate carcinoma: Methodology, feasibility, surgical, and oncological consequences: A prospective study about 93 patients. ( E6 )
Claude Soler - CHPL, Centre d'Imagerie Nucleaire
Abstract # 70 : Prior cancer diagnosis in men with nonmetastatic prostate cancer and the risk of prostate cancer specific and all-cause mortality. ( E7 )
Kristina Mirabeau-Beale - Harvard Radiation Oncology Program
Abstract # 71 : Severe lack of comprehension of common prostate health terminology in underserved populations: External validation. ( E8 )
Viraj A. Master - Emory University
Abstract # 72 : Chimeric antigen receptor (CAR+) modified T cells targeting prostate-specific membrane antigen (PSMA) in patients (pts) with castrate metastatic prostate cancer (CMPC). ( E9 )
Susan F. Slovin - Sidney Kimmel Center for Prostate and Urologic Cancers, Memorial Sloan-Kettering Cancer Center
Abstract # 73 : Quantifying the ki-67 heterogeneity profile in prostate cancer. ( E10 )
Mitchell Kamrava - Department of Radiation Oncology, David Geffen School of Medicine at University of California, Los Angeles
Abstract # 74 : Relationship of sipuleucel-T with time to first use of opioid analgesics (TFOA) in patients (pts) with asymptomatic or minimally symptomatic metastatic castration-resistant prostate cancer (mCRPC) on the IMPACT trial. ( E11 )
Eric Jay Small - Helen Diller Family Comprehensive Cancer Center, University of California
Abstract # 75 : Association of germ-line genetic variation in the NK3 homeobox 1 gene with overall survival in advanced-stage castrate-resistant prostate cancer (CRPC). ( E12 )
Manish Kohli - Mayo Clinic
Abstract # 76 : Feasibility of RNA sequencing to detect TMPRSS2:ERG fusions following laser capture microdissection of prostate cancer. ( E13 )
Won Kim - University of California, San Francisco
Abstract # 77 : Population-based impact on overall survival (OS) after the introduction of docetaxel as standard therapy for metastatic castration resistant prostate cancer (CRPC). ( E14 )
Robert Richard Zielinski - British Columbia Cancer Agency
Abstract # 78 : Maximum tumor diameter as a predictor for outcome following salvage radiation for prostate cancer. ( E15 )
Skyler B. Johnson - University of Michigan
Abstract # 79 : Sequencing of cabazitaxel and abiraterone acetate following docetaxel in metastatic castration-resistant prostate cancer (mCRPC). ( E16 )
Ian D. Schnadig - Compass Oncology, McKessson Specialty Health
Abstract # 80 : Genomic analysis of prostate cancer. ( E17 )
Christine M. Barnett - Oregon Health and Science University, Knight Cancer Institute
Abstract # 81 : Relationship of oral glycine with radiation-induced HIF1-alpha and tumor growth delay in a prostate cancer xenograft. ( E18 )
Elizabeth Riley Kessler - University of Colorado Denver
Abstract # 82 : Age, comorbidity, and the risk of death in men with PSA failure following radiation therapy. ( F1 )
Neil E. Martin - Dana-Farber Cancer Institute/Brigham and Women's Hospital
Abstract # 83 : Intermediate versus short-course hormone therapy and mortality in men with high-risk prostate cancer treated with radiation therapy. ( F2 )
Akash Nanda - MD Anderson Cancer Center Orlando
Abstract # 84 : Prediction of patient-reported bowel quality of life (QOL) after dose-escalated radiation therapy (RT) for prostate cancer by rectal dosimetry. ( F3 )
Matthew H. Stenmark - University of Michigan Medical Center
Abstract # 85 : Safety profile of poxviral vaccines: NCI experience. ( F4 )
Joseph W. Kim - Laboratory of Tumor Immunology and Biology, Medical Oncology Branch, National Cancer Institute
Abstract # 86 : Importance of Gleason score on 18F-choline PET/CT findings in patients with biochemical relapse of prostate cancer disease (PSA<1.0 ng/ml). ( F5 )
Marina Hodolic - University Medical Centre Ljubljana
Abstract # 87 : Association of cross-talk between α1D-adrenergic receptor (α1D -AR) and transient receptor potential vanilloid 1 (TRPV1) with the proliferation of PC3 prostate cancer cells. ( F6 )
Giorgio Santoni - School of Pharmacy, Experimental Medicine Section, University of Camerino
Abstract # 88 : Association of declining PSA values with a lower risk of progression in the Canary Prostate Cancer Active Surveillance Study (PASS). ( F7 )
James D. Brooks - Stanford University
Abstract # 89 : Is there a withdrawal syndrome with abiraterone acetate (AA)? ( F8 )
Laurence Albiges - Institut Gustave Roussy
Abstract # 90 : Impact of intermittent (I) first-line docetaxel (D)-based chemotherapy on quality of life (QL) of patients (pts) with castration-resistant prostate cancer (CRPC): Results of a phase II randomized trial. ( F9 )
Orazio Caffo - Medical Oncology Santa Chiara Hospital
Abstract # 91 : Cabazitaxel for metastatic castration-resistant prostate cancer (mCRPC): Final quality-of-life (QOL) results with safety data from the United Kingdom (UK) Early Access Programme (EAP) (NCT01254279). ( F10 )
Amit Bahl - Bristol Haematology and Oncology Centre
Abstract # 92 : Trans-Pacific variation in outcomes for men treated with primary androgen deprivation therapy for localized prostate cancer. ( F11 )
Matthew R. Cooperberg - University of California, San Francisco
Abstract # 93 : Long-term health-related quality of life in patients treated for localized prostate cancer. ( F12 )
Sanoj Punnen - University of California, San Francisco
Abstract # 94 : Effect of generation 2.5 antisense inhibitor of androgen receptor on MDV3100-resistant prostate cancer cell growth in vitro and in vivo. ( F13 )
Yoshiaki Yamamoto - Vancouver Prostate Centre
Abstract # 95 : Prediction of risk for prostate cancer in histopathologically negative biopsies by multigene epigenetic assay. ( F14 )
Leander Van Neste - MDxHealth
Abstract # 96 : Phase I trial of total androgen blockade, weekly docetaxel, and image-guided intensity-modulated radiotherapy for localized high-risk prostate adenocarcinoma. ( F15 )
Stephen J. Ramey - Medical University of South Carolina
Abstract # 97 : Pretreatment serum biomarkers and clinical outcome in the phase II trial of zibotentan (endothelin A receptor antagonist) in metastatic CRPC. ( F16 )
Ajit Kumar Bisen - Penn State Milton S. Hershey Medical Center (First Author: Julia Shelkey - Penn State Milton S. Hershey Medical Center )
Abstract # 98 : Racial differences in survival outcomes among men with localized prostate cancer. ( F17 )
Grace L. Lu-Yao - Cancer Institute of New Jersey, Robert Wood Johnson Medical School, University of Medicine and Dentistry of New Jersey
Abstract # 99 : Hemi salvage HIFU in patients with radio recurrent prostate cancer: Early experience and results. ( F18 )
Gilles Pasticier - Urology Department, University Hospital of Bordeaux
Abstract # 100 : Aldo-keto reductase (AKR) 1C3 as an androgen receptor coactivator. ( G1 )
Ramesh Narayanan - GTx, Inc.
Abstract # 101 : Effect of inhibition of the PI3K/Akt/mTOR pathway on AR splicing and downstream targets. ( G2 )
XiaoMei Liu - New York University Cancer Institute
Abstract # 102 : A phase II randomized clinical trial of samarium-153 EDTMP (Sm-153) with or without PSA-tricom vaccine in metastatic castration-resistant prostate cancer (mCRPC) after docetaxel. ( G3 )
Christopher Ryan Heery - Laboratory of Tumor Immunology and Biology, Medical Oncology Branch, National Cancer Institute
Abstract # 103 : Preliminary results of a prospective study of 18F-NAF PET/CT in prostate cancer. ( G4 )
Jong Chul PARK - National Cancer Institute
Abstract # 104 : Effect of Gtx-758, an ERα agonist, on serum-free testosterone and serum PSA in men with advanced prostate cancer. ( G5 )
Evan Y. Yu - Fred Hutchinson Cancer Research Center
Abstract # 105 : A phase II trial of temsirolimus in men with castration-resistant metastatic prostate cancer. ( G6 )
Andrew J. Armstrong - Duke Cancer Institute, Duke University Medical Center
Abstract # 106 : Bone health among prostate cancer survivors: Long-term follow-up from the Prostate Cancer Outcomes Study (PCOS). ( G7 )
Alicia Katherine Morgans - Vanderbilt-Ingram Cancer Center
Abstract # 107 : Utilization and cancer detection by U.S. prostate biopsies (2005-2011). ( G8 )
Carl A. Olsson - Integrated Medical Professionals, PLLC; Columbia University Medical Center
Abstract # 108 : Activity of gemcitabine-oxalipaltin (GemOx) plus prednisolone in patients with castration-resistant prostate cancer (CRPC) for whom docetaxel-based chemotherapy failed. ( G9 )
Jae-Lyun Lee - Department of Oncology, Asan Medical Center, University of Ulsan College of Medicine
Abstract # 109 : Association of metastasis-free survival (MFS) with overall survival (OS) in men with PSA-recurrent prostate cancer treated with deferred androgen-deprivation therapy. ( G10 )
Michael Thomas Schweizer - The Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins
Abstract # 110 : Ex-vivo prostate cancer explant organ culture model system for targeted drug development in prostate cancer ( G11 )
Shilpa Gupta - H. Lee Moffitt Cancer Center & Research Institute
Abstract # 111 : Study of the impact of Charlson comorbidity index and hypertension on survival in patients with metastatic castration-resistant prostate cancer. ( G12 )
Jatinder Goyal - University of Alabama at Birmingham Medical Center
Abstract # 112 : Comparison of PSA slope and nadir between hypofractionated SBRT and conventionally fractionated EBRT. ( G13 )
Mekhail Anwar - University of California, San Francisco
Abstract # 113 : A multicenter population-based experience with abiraterone acetate (AA) in patients with metastatic castration resistant prostate cancer (mCRPC). ( G14 )
Ravinder Clayton - Tom Baker Cancer Centre
Abstract # 114 : A randomized phase II, open-label study of sipuleucel-T with concurrent or sequential abiraterone acetate (AA) in metastatic castrate-resistant prostate cancer (mCRPC). ( G15 )
Eric Jay Small - University of California, San Francisco
Abstract # 115 : Risk assessment for severe hypocalcemia requiring hospitalization with denosumab. ( G16 )
Karen A. Autio - Memorial Sloan-Kettering Cancer Center
Abstract # 116 : Epigenetic field effect markers as indicative of occult high-grade prostate cancer. ( G17 )
Sandra Marlene Gaston - New England Baptist Hospital
Abstract # 117 : Disparities in prostate cancer treatment associated with population density of the county of residence. ( G18 )
Clint Cary - University of California, San Francisco
Abstract # 118 : Influence of ischemia on tissue androgens in eugonadal and androgen-deprived men treated with prostatectomy. ( H1 )
Robert B. Montgomery - University of Washington
Abstract # 119 : Prostate-specific membrane antigen antibody drug conjugate (PSMA ADC): A phase I trial in metastatic castration-resistant prostate cancer (mCRPC) previously treated with a taxane. ( H2 )
Daniel Peter Petrylak - Columbia University Medical Center
Abstract # 120 : Patient-reported sexual and urinary function after open and robotic radical prostatectomy. ( H3 )
Joseph C. Klink - Glickman Urological & Kidney Institute, Cleveland Clinic
Abstract # 121 : Phase II trial of 177lutetium radiolabeled anti-PSMA antibody J591 (177Lu-J591) for metastatic castrate-resistant prostate cancer (metCRPC): Survival update and expansion cohort with biomarkers. ( H4 )
Scott T. Tagawa - Weill Cornell Medical College
Abstract # 122 : Retrospective registry evaluating the PSA flare phenomenon with cabazitaxel in metastatic castration-resistant prostate cancer (mCRPC). ( H5 )
Antoine Angelergues - Department of Medical Oncology, Georges Pompidou European Hospital
Abstract # 123 : A randomized phase II trial of dexamethasone versus prednisolone as secondary hormonal therapy in CRPC. ( H6 )
Ramachandran Venkitaraman - Ipswich Hospital NHS
Abstract # 124 : Comparison of survival rates of patients (pts) with localized prostate cancer (T1-2N0M0) treated with brachytherapy (BT) and external beam radiation therapy (EBRT): Surveillance Epidemiology and End Results (SEER) database review. ( H7 )
Anteneh A. Tesfaye - McLaren Flint Medical Center/Michigan State University
Abstract # 125 : From trial to practice: The Princess Margaret Hospital (PMH) experience with docetaxel and prednisone for men with metastatic castration resistant prostate cancer (mCRPC). ( H8 )
Arnoud Templeton - Division of Medical Oncology, Princess Margaret Hospital
Abstract # 126 : Absence of interaction of cabazitaxel on the pharmacokinetics of midazolam: Results of a drug–drug interaction study in patients with advanced solid tumors. ( H9 )
Olivier Rixe - Georgia Health Sciences University
Abstract # 127 : Stratification of risk for patients with prostate cancer at biopsy using CCP score. ( H10 )
Neal D. Shore - Carolina Urologic Research Center
Abstract # 128 : Use of supportive measures to improve outcome and decrease toxicity in docetaxel-based antiangiogenesis combinations. ( H11 )
Fatima H. Karzai - Medical Oncology Branch, National Cancer Institute
Abstract # 129 : Rate of hot flashes in patients with advanced prostate cancer treated with GTx-758. ( H12 )
Evan Y. Yu - University of Washington and Seattle Cancer Care Alliance
Abstract # 130 : Analysis of putative resistance mechanisms in recent treatments targeting the androgen receptor in castration-resistant prostate cancer (CRPC). ( H13 )
Paul Thelen - Georg-August-University
Abstract # 131 : Real-world experience with sipuleucel-T in patients (pts) ≥80 years old with metastatic castration-resistant prostate cancer (mCRPC): Data from PROCEED.^ ( H14 )
Chadi Nabhan - Oncology Specialists SC, Lutheran General Hospital
Abstract # 132 : Feasibility of continuing docetaxel-based therapy in patients with metastatic castrate-resistant prostate cancer (mCRPC) that experience hypersensitivity reactions (HSR). ( H15 )
Anna Couvillon - Medical Oncology Branch, National Cancer Institute
Abstract # 133 : Predictors and prognostic implication of pathologic fracture (PF), spinal cord compression (SCC), and bone surgery (BS) following diagnosis of metastatic prostate cancer (PCa). ( H16 )
Ebere Onukwugha - University of Maryland School of Pharmacy
Abstract # 134 : Early response assessment and bone flare phenomenon on 18F-fluorocholine positron emission tomography/computed tomography (FCH-PET/CT) in patients (pts) with metastatic castration-resistant prostate cancer (CRPC) treated with abiraterone acetate. ( H17 )
Salvatore Luca Burgio - IRCCS Istituto Scientifico Romagnolo per lo Studio e la Cura dei Tumori (I.R.S.T.)
Abstract # 135 : Long-term immune responses elicited by a DNA vaccine encoding prostatic acid phosphatase (PAP) in patients with nonmetastatic castrate-resistant prostate cancer. ( H18 )
Douglas G. McNeel - University of Wisconsin Carbone Cancer Center
Abstract # 136 : Are PSA baseline levels an indicator for suitability of intermittent androgen deprivation in patients with PSA relapse after radical prostatectomy? ( J1 )
Ulf W. Tunn - Urological Clinic and Prostate Center, Facharztzentrum Klinikum Offenbach
Abstract # 137 : Efficacy of cabazitaxel and its relationship with predictors of poor response to second hormonal therapies (2d HT) in metastatic castration-resistant prostate cancer (mCRPC). ( J2 )
Stephane Oudard - Department of Medical Oncology, Georges Pompidou European Hospital
Abstract # 138 : Induction of endothelial proliferation and angiogenesis through activating the ERK1/2/EGF pathway mediate by CXC chemokine receptor 2 by chemokine (C-X-C motif) ligand 1. ( J3 )
Makito Miyake - MD Anderson Cancer Center Orlando
Abstract # 139 : Value of NADiA ProsVue on the CAPRA-s nomogram for predicting postprostatectomy clinical recurrence. ( J4 )
Judd W. Moul - Duke University Medical Center
Abstract # 140 : Overtreatment of prostate cancer in Florida. ( J5 )
Scott Michael Gilbert - University of Florida
Abstract # 141 : Hypofractionated radiotherapy (66Gy at 3Gy per fraction) for favorable-risk prostate cancer: Long-term outcomes. ( J6 )
Nita Patel - McGill University Health Centre
Abstract # 142 : A phase Ib trial of mushroom powder in biochemically recurrent, hormone-naive prostate cancer. ( J7 )
Przemyslaw Twardowski - City of Hope
Abstract # 143 : Quality-of-life outcomes for prostate cancer treatment in Australia. ( J8 )
Jeremy L. Millar - Department of Epidemiology and Preventive Medicine
Abstract # 144 : Detection and genomic interrogation of circulating tumor cells (CTCs) and circulating tumor stem cells (CTSCs) from men with metastatic castration-resistant prostate cancer (mCRPC). ( J9 )
Terence W. Friedlander - University of California, San Francisco
Abstract # 145 : Dose-escalated adaptive image-guided radiotherapy versus high-dose-rate brachytherapy monotherapy for low-risk prostate cancer. ( J10 )
Ovidiu Marina - William Beaumont Hospital
Abstract # 146 : Comparison of abiraterone acetate (Abi) versus ketoconazole (Keto) in patients (pts) with metastatic castration-resistant prostate cancer (mCRPC) refractory to docetaxel (D). ( J11 )
Avivit Peer - Rambam Health Care Campus
Abstract # 147 : P10-1 open-label, multicenter study of sipuleucel-T in metastatic castrate-resistant prostate cancer (mCRPC) patients (pts) previously treated with sipuleucel-T: Evaluation of antigen-presenting cell (APC) activation. ( J12 )
L. Michael Glode - University of Colorado, Denver (First Author: Tomasz M. Beer - Oregon Health and Science University, Knight Cancer Institute)
Abstract # 148 : Immune response with sipuleucel-T in patients (pts) with metastatic castration-resistant prostate cancer (mCRPC): Phase II ProACT study. ( J13 )
Thomas A. Gardner - Simon Cancer Center, Indiana University
Abstract # 149 : Location of local recurrence after MRI-guided partial prostate brachytherapy targeting only the peripheral zone: Implications for focal therapy. ( J14 )
Konstantin Kovtun - Dana-Farber Cancer Institute/Brigham and Women's Hospital, Harvard Medical School
Abstract # 150 : Concurrent treatment with everolimus (RAD001) and hormonoradiotherapy in high-risk locally advanced prostate cancer: Results of a phase I trial. ( J15 )
David Azria - CRLC Val d'Aurelle
Abstract # 151 : Gleason pattern 5 is the strongest pathologic predictor of recurrence, development of metastasis, and prostate cancer-specific death for patients receiving salvage radiation therapy following radical prostatectomy. ( J16 )
William C. Jackson - University of Michigan
Abstract # 152 : Prognostic value of free testosterone (FT) levels during salvage chemotherapy with carboplatin plus weekly docetaxel in metastatic castration- and docetaxel-resistant prostate cancer (mDRPC). ( K1 )
Christoph W. Reuter - Department of Hematology, Hemostasis, Oncology, and Stem Cell Transplantation, Hannover Medical School
Abstract # 153 : Results of a phase II study of sunitinib (SU) maintenance after response to docetaxel in metastatic castration-resistant prostate cancer (mCRPC). ( K2 )
Bernhard J. Eigl - British Columbia Cancer Agency - Vancouver Cancer Centre
Abstract # 154 : Sensitivity of PTEN-deficient prostate carcinoma cells to ionizing radiation through inhibition of treatment-induced CXCL8 signaling. ( K3 )
Chris Armstrong - Queen's University Belfast
Abstract # 155 : Response to cabazitaxel in CRPC patients previously treated with docetaxel and abiraterone acetate. ( K4 )
Carmel Jo Pezaro - The Institute of Cancer Research and The Royal Marsden NHS Foundation Trust
Abstract # 156 : Phase II trial of combination therapy with intravenous carboplatin (C) and oral everolimus (EVE) and prednisone (P) in docetaxel pretreated (DP) metastatic castrate-resistant prostate cancer (mCRPC): A Prostate Cancer Clinical Trial Consortium study. ( K5 )
Muthu Kumaran Veeraputhiran - Karmanos Cancer Institute
Abstract # 157 : Assocation of Gleason 9-10 prostate cancer with worse outcomes compared to Gleason 8 disease. ( K6 )
Che-Kai Tsao - Division of Hematology and Medical Oncology, The Tisch Cancer Institute, Mount Sinai School of Medicine
Abstract # 158 : Multiplexed protein and gene profiling of circulating tumor cells (CTCs) in metastatic castration-resistant prostate cancer (mCRPC) using automated immunofluorescence and fluorescence in situ hybridization. ( K7 )
Dea Nagy - Ventana Medical Systems, Inc.
Abstract # 159 : Is there a predictive value for measurement of tumor percentage and the number of tumor foci after prostatectomy? ( K8 )
Reemt Hinkelammert - Prostate Center, Department of Urology, University Hospital Muenster
Abstract # 160 : Influence of concurrent medications on PSA doubling time (PSADT) in patients (pts) with nonmetastatic biochemically relapsed prostate cancer (BRPC M0) after local therapy (tx). ( K9 )
Daniel Keizman - Genitourinary Oncology Service, Division of Oncology, Meir Medical Center, Sackler School of Medicine, Tel Aviv University
Abstract # 161 : Overtreatment of low-risk prostate cancer in the United States: Incidence, cost, complications, and implications for the screening debate. ( K10 )
Ayal A. Aizer - Harvard Radiation Oncology Program
Abstract # 162 : Effectiveness of abiraterone as salvage therapy in patients with docetaxel- and castration-resistant prostate cancer (mDCPC) that progressed during second-line chemotherapy with carboplatin plus weekly docetaxel (DC). ( K11 )
Christoph W. Reuter - Department of Hematology, Hemostasis, Oncology, and Stem Cell Transplantation, Hannover Medical School
Abstract # 163 : Castration resistance and risk of bone metastases among men with nonmetastatic prostate cancer on androgen-deprivation therapy: A population-based cohort study from the Henry Ford Health System (HFHS) in Detroit, Michigan. ( K12 )
Jennifer Beebe-Dimmer - Karmanos Cancer Institute Division of Population Studies and Disparities Research, Wayne State University Department of Oncology
Abstract # 164 : Effect of Wnt-1 induced signaling protein-2 (Wisp-2/CCN5) on angiogenesis and invasion in prostate cancer. ( K13 )
Yasunobu Hashimoto - Department of Urology, Tokyo Women's Medical University Aoyama Hospital, Japan
Abstract # 165 : Stereotactic body radiation therapy (SBRT) following procedures for benign prostatic hyperplasia (BPH): A report on early toxicity. ( K14 )
Marie Kate Gurka - Georgetown University Hospital
Abstract # 166 : Serum insulin-like growth factor-1 levels in response to dasatinib-based regimens in bone-metastatic prostate cancer. ( K15 )
Farshid Dayyani - The University of Texas MD Anderson Cancer Center
Abstract # 167 : PSA doubling time of ≤6 months is the optimal cut-off for predicting clinically relevant outcomes for men receiving salvage radiation therapy post radical prostatectomy. ( K16 )
William C. Jackson - University of Michigan
Abstract # 168 : Long-term tolerance of neoaduvant docetaxel/estramustine chemotherapy in patients with high-risk localized prostate cancer treated at IGR in the GETUG 12 phase III trial. ( L1 )
Pierre-Olivier Bosset - Institut Gustave Roussy
Abstract # 169 : Use of biopsy detail to identify subgroup risk in high-risk patients with prostate cancer. ( L2 )
Natasha C. Townsend - Fox Chase Cancer Center
Abstract # 170 : Long-term outcomes of active surveillance for prostate cancer: 10 years later. ( L3 )
David D. Buethe - Moffitt Cancer Center and Research Institute
Abstract # 171 : Serum IGF-1 levels are decreased in men with advanced prostate cancer treated with the ERα agonist, gtx-758. ( L4 )
Evan Y. Yu - Fred Hutchinson Cancer Research Center
Abstract # 172 : Pathologic findings in additional prostatic and periprostatic tissue removed during radical prostatectomy. ( L5 )
Henry Chen - Michigan State University
Abstract # 173 : Effect of PEDF on the in vivo antitumor activities of low-dose chemotherapy in CRPC. ( L6 )
Thomas Nelius - Texas Tech University Health Sciences Center
Abstract # 174 : Variations in treatment modality use for the definitive management of prostate cancer in the United States. ( L7 )
Jay P. Ciezki - Cleveland Clinic
General Poster Session B: Prostate, Penile, Urethral, Urothelial, and Testicular Cancers
Abstract # 246 : Novel definition of BCG failure to enhance recruitment into clinical trials. ( A1 )
Daniel Levi Willis - The University of Texas MD Anderson Cancer Center
Abstract # 247 : Genomic characterization of metastatic urothelial carcinoma. ( A2 )
Richard M. Bambury - Memorial Sloan-Kettering Cancer Center and Weill Cornell Medical College
Abstract # 248 : Clinical-pathologic stage discrepancy in patients with bladder cancer treated with radical cystectomy: Associations with clinical variables and survival. ( A3 )
Phillip J. Gray Harvard Radiation Oncology Program
Abstract # 249 : Randomized phase III trial of neoadjuvant chemotherapy (NAC) with methotrexate, doxorubicin, vinblastine, and cisplatin (MVAC) followed by radical cystectomy (RC) compared with RC alone for invasive bladder cancer (BC): Japan Clinical Oncology Group Study, JCOG0209. ( A4 )
Hiroshi Kitamura - School of Medicine, Sapporo Medical University
Abstract # 250 : Randomized phase III study of adjuvant versus progression-triggered treatment with gemcitabine (G) after radical cystectomy (RC) for locally advanced bladder cancer (LABC) in patients not suitable for cisplatin-based chemotherapy (CBC) (AUO-trial AB22/00). ( A5 )
Jan Lehmann - Department of Urology, Saarland University
Abstract # 319 : Prediction of relapse in stage I nonseminomatous germ cell tumors (NSGCT) by CXCL12: Results from the MRC TE08 and TE22 clinical trials. ( A6 )
Duncan Charles Gilbert - Sussex Cancer Centre
Abstract # 320 : Cost analysis of adjuvant management strategies in early-stage testicular seminoma. ( A7 )
John A. Cox - Department of Radiation Oncology, The University of Texas Medical Branch
Abstract # 175 : Patients less likely to benefit from salvage radiation for prostate cancer. ( A8 )
Brian Joseph Gebhardt - Medical College of Georgia
Abstract # 176 : Impact of body mass index on clinicopathologic outcome and biochemical recurrence after radical prostatectomy in 1,257 Japanese patients with prostate cancer. ( A9 )
Shintaro Narita - Department of Urology, Akita University School of Medicine
Abstract # 177 : Prostate cancer (PC) follow-up and treatment by race in an equal access health system: A pilot study. ( B1 )
Nirupama Devi Mitikiri - University of Maryland Medical Center
Abstract # 178 : Specification and validation of prostate cancer quality-of-care e-measures in the Veterans Health Administration (VHA). ( B2 )
Jeremy B. Shelton - VA Greater Los Angeles Healthcare System; Department of Urology, University of California, Los Angeles
Abstract # 179 : Circulating tumor cells (CTCs) in biochemical recurrence (BR) of prostate cancer: Final results. ( B3 )
Jeanny B. Aragon-Ching - George Washington University Medical Center
Abstract # 180 : Heterogeneity of treatment effects (HTE) in stage IV prostate cancer (S4PC). ( B4 )
Nirupama Devi Mitikiri - University of Maryland Medical Center
Abstract # 181 : 15-year survival after radical prostatectomy (RP): Which prognostic factors are available for patient counseling? ( B5 )
Sophie D. Fossa - Oslo University Hospital, The Norwegian Radium Hospital
Abstract # 182 : Genetic instability after radiotherapy in prostate cancer: TMRSS2-ERG fusion in salvage radical prostatectomies. ( B6 )
David J. K. P. Pfister - Rheinisch-Westfaelische Technische Hochschule Aachen
Abstract # 183 : Improved wait time intervals for patients with prostate cancer in a multidisciplinary rapid diagnostic unit compared to a community-based referral pattern. ( B7 )
Perakaa Sethukavalan - Sunnybrook Health Sciences Centre
Abstract # 184 : Differential effects of galeterone, abiraterone, orteronel, and ketoconazole on CYP17 and steroidogenesis. ( B8 )
Douglas Burtner Jacoby - Tokai Pharmaceuticals
Abstract # 185 : Prevalence of cardiovascular disease (CVD) risk factors and receipt of preventive care among prostate cancer (CaP) survivors in the United States. ( B9 )
Kevin A. Pearlstein - The University of North Caroline-Chapel Hill, School of Medicine
Abstract # 186 : Activity of cabazitaxel following docetaxel and abiraterone acetate in patients with castration-resistant prostate cancer. ( B10 )
Avishay Sella - Assaf Harofeh Medical Center
Abstract # 187 : Photoselective vaporization of the prostate compared to transurethral resection of the prostate in patients who develop prostatic obstruction following brachytherapy. ( B11 )
Benjamin Abelson - Cleveland Clinic
Abstract # 188 : 11c-choline PET/CT in selection of patients for salvage cryoablation in recurrent prostate cancer. ( B12 )
Anthonius J. Breeuwsma - Department of Urology, University Medical Center Groningen
Abstract # 189 : Which data for cabazitaxel (Cbz) from the real world? The safety experience from the Italian centres participating in the Expanded Access Programme (EAP). ( B13 )
Giuseppe Fornarini - Ospedale San Martino (First Author: Sergio Bracarda - Department of Oncology, USL-8, Ospedale San Donato)
Abstract # 190 : Dependence of intrafraction prostate motion within the pelvis on fraction duration during whole pelvic intensity modulated arctherapy (IMAT) versus dynamic IMRT. ( B14 )
Nicolas Lescut - Georges Francois Leclerc Cancer Center, Burgundy
Abstract # 191 : Beyond IGRT: Daily real time planning (RTP)—Treatment of prostate cancer, clinical implementation, and technique. ( B15 )
James Robert Wong - Morristown Medical Center
Abstract # 192 : Trends in use of intravenous bisphosphonates in patients with prostate cancer and newly diagnosed metastases to bone in two large U.S. integrated health systems. ( B16 )
Lois Lamerato - Henry Ford Health System
Abstract # 193 : Phase I dose escalation trial of MVA-BN-PRO in men with nonmetastatic castration-resistant prostate cancer. ( B17 )
David G. McLeod - Walter Reed National Military Medical Center
Abstract # 194 : Use of microRNA signature to distinguish early from late biochemical failure in prostate cancer. ( B18 )
Zsuzsanna Lichner - Li Ka Shing Knowledge Institute at St. Michael's Hospital
Abstract # 195 : Evolving patterns of metastatic disease in castration-resistant prostate cancer (CRPC) reported in clinical trials from 1990 to 2011. ( C1 )
William K. Oh - Division of Hematology and Medical Oncology, The Tisch Cancer Institute, Mount Sinai School of Medicine
Abstract # 196 : Evaluation of a genomic-based prognostic test for metastasis in high-risk post-prostatectomy patients: Does it impact physician decision making? ( C2 )
Ketan K. Badani - Department of Urology, Columbia University College of Physicians & Surgeons
Abstract # 197 : A phase II study of linsitinib (OSI-906) in patients with asymptomatic or mildly symptomatic (non-opioid requiring) metastatic castrate resistant prostate cancer (CRPC). ( C3 )
Jorge A. Garcia - Cleveland Clinic
Abstract # 198 : Utility of blood oxygen level dependent magnetic resonance imaging in the evaluation of tissue oxygenation patterns of prostate cancer. ( C4 )
Bishoy A. Gayed - The University of Texas Southwestern Medical Center
Abstract # 200 : Novel methodology for cost evaluation of anticancer drugs in castrate-resistant prostate cancer. ( C6 )
Helmy M. Guirgis - University of California, Irvine
Abstract # 201 : Stability of white blood cell counts following standard radiation approaches for high-risk adenocarcinoma of the prostate: Implications for combination therapy. ( C7 )
Steven E. Finkelstein - 21st Century Oncology, Translational Research Consortium (TRC)
Abstract # 202 : Impact of magnetic resonance imaging (MRI) in the local staging, risk group classification, and treatment of patients with prostate cancer with combination of high dose rate (HDR) brachytherapy and external beam radiotherapy (EBRT). ( C8 )
Alfonso Gomez-Iturriaga - Hospital Universitario de Cruces
Abstract # 203 : Health services utilization differences between patients with metastatic (M1) and nonmetastatic (M0) prostate cancer (PCa). ( C9 )
Candice Yong - University of Maryland School of Pharmacy
Abstract # 204 : Certificate of need and use of IMRT in elderly patients with low-risk prostate cancer. ( C10 )
Grace L. Lu-Yao - Cancer Institute of New Jersey, Robert Wood Johnson Medical School, University of Medicine and Dentistry of New Jersey
Abstract # 205 : G-CSF utilization during abiraterone acetate (AA) and cabazitaxel (C) therapy: A retrospective U.S. claims analysis. ( C11 )
Maneesha Mehra - Janssen Global Services
Abstract # 206 : Efficacy and toxicity of q 2 weeks versus weekly versus q 3 weeks docetaxel in metastatic castration-resistant prostate cancer (CRPC). ( C12 )
Akshiv Malhotra - SUNY Upstate Medical University
Abstract # 207 : Current status and outcomes of salvage radiotherapy for patients with PSA recurrence after prostatectomy: A JROSG surveillance study. ( C13 )
Takashi Mizowaki - Kyoto University
Abstract # 208 : Clinical outcomes and toxicity of estramustine phosphate (EP) addition to docetaxel (D) as first-line therapy for castration-resistant prostate cancer (CRPC): A cumulative analysis on 243 patients (pts) from two randomized phase II trials. ( C14 )
Orazio Caffo - Medical Oncology Santa Chiara Hospital
Abstract # 209 : A pilot study of high-dose exisulind in men with biochemical relapse (BCR) of prostate cancer after definitive local therapy treated with intermittent androgen deprivation (IAD). ( C15 )
Evan Y. Yu - University of Washington and Seattle Cancer Care Alliance
Abstract # 210 : Time to follow-up and treatment in patients with newly diagnosed prostate cancer (PC) across clinical stages in an equal access health system. ( C16 )
Anitha Nallu - University of Maryland Medical Center
Abstract # 211 : Who dies from prostate cancer in a Western country? A multicenter analysis. ( C17 )
Yohann Loriot - Institut Gustave Roussy
Abstract # 212 : C35: A new prognostic tool and potential target in prostate cancer. ( C18 )
Deepak Kilari - University of Rochester
Abstract # 213 : High-dose-rate brachytherapy combined with external beam radiotherapy for localized prostate cancer: Correlation between clinical and dosimetric parameters and the incidence of rectal bleeding. ( D1 )
Shinji Kariya - Kochi Medical School
Abstract # 214 : Effect of simultaneous blockade of androgen and estrogen receptors on prostate cancer: In vivo study. ( D2 )
Rafael Nunez-Nateras - Mayo Clinic
Abstract # 215 : Diagnostic accuracy of PET scan in salvage lymph node resections in patients with prostate cancer (CaP). ( D3 )
David J. K. P. Pfister - Rheinisch-Westfaelische Technische Hochschule Aachen
Abstract # 216 : Phase I trial data in prostate cancer suggest critical role for IL2 adjunctive cotherapy for successful suppression of solid tumor with designer T cells. ( D4 )
Richard Paul Junghans - Roger Williams Medical Center
Abstract # 217 : Comparative effective analysis between enzalutamide and abiraterone in the treatment of metastatic castration-resistant prostate cancer. ( D5 )
Akhil Chopra - Johns Hopkins Singapore International Medical Center
Abstract # 218 : Salvage brachytherapy for prostate bed recurrence following radical prostatectomy. ( D6 )
Kristin Smith - Cleveland Clinic
Abstract # 219 : A prostate cancer clinical trials consortium trial of disulfiram (D) in men with nonmetastatic recurrent prostate cancer (PCa). ( D7 )
Michael Thomas Schweizer - The Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins
Abstract # 220 : Patient-reported quality of life in men with turps undergoing proton therapy for prostate cancer. ( D8 )
Derek Lee - University of Florida Proton Therapy Institute
Abstract # 221 : Arachidonic acid drives amoeboid transendothelial invasion through ligand independent activation of EphA2. ( D9 )
Mick D. Brown - Faculty Institute of Cancer Sciences
Abstract # 222 : Effect of the ERα agonist GTx-758 on bone turnover markers in men with advanced prostate cancer. ( D10 )
Evan Y. Yu - Fred Hutchinson Cancer Research Center
Abstract # 223 : Is routine prostate biopsy needed prior to radical cystectomy? ( D11 )
Yasuhiro Hashimoto - Department of Urology, Hirosaki University Graduate School of Medicine
Abstract # 224 : Cabazitaxel in patients with metastatic castrate-resistant prostate cancer previously treated with a docetaxel-containing regimen: A single U.K. cancer center's experience using Early Access Programme and Cancer Drugs Fund. ( D12 )
Claire L. S. Kelly - Rosemere Cancer Centre, Royal Preston Hospital
Abstract # 225 : Incidental prostate cancer in patients with radical cystectomy for bladder cancer. ( D13 )
Hooman Djaladat - Institute of Urology, University of Southern California
Abstract # 226 : Characteristics and outcomes of elderly patients with systemic prostate cancer (PCa) treated with peripheral androgen blockade (PAB). ( D14 )
Deepak Kilari - University of Rochester
Abstract # 227 : A novel method for decreasing rectal toxicity during prostate radiotherapy by prostate-rectum separation: An evaluation of irradiation dose parameters and acute side effects. ( D15 )
Michael J. Mathers - Urologische Gemeinschaftspraxis Remscheid in cooperation with the Urological Clinic Wuppertal, Universitiy Witten/Herdecke
Abstract # 228 : Cell-free DNA as a prognostic marker for response to taxan-based chemotherapy in patients with prostate cancer (CaP). ( D16 )
Alexandra Kienel - Rheinisch-Westfaelische Technische Hochschule Aachen
Abstract # 229 : Potential cost-effectiveness of a diagnostic that identifies localized versus metastatic prostate cancer in men with biochemical recurrence after radical prostatectomy. ( D17 )
Mark Eliot Bensink - Fred Hutchinson Cancer Research Center
Abstract # 230 : Phase II trial of acai juice product in biochemically recurrent prostate cancer. ( D18 )
Elizabeth Riley Kessler - University of Colorado Denver
Abstract # 231 : Utilization of local salvage therapy after primary radiotherapy for prostate cancer. ( E1 )
Henry Tran - Department of Urologic Sciences, The University of British Columbia
Abstract # 232 : Dosimetic quality and evolution of edema after prostate brachytherapy for small prostates: Implications for the use of newer isotopes. ( E2 )
Konstantin Kovtun - Dana-Farber Cancer Institute/Brigham and Women's Hospital, Harvard Medical School
Abstract # 233 : The use of electromagnetic transponder beacons to reduce planning target volume (PTV) margins in post-prostatectomy patients undergoing adjuvant or salvage radiation therapy. ( E3 )
Madeera Kathpal - University of Medicine and Dentistry of New Jersey
Abstract # 234 : Postdocetaxel treatment for castrate-resistant prostate cancer: The sequential use of abiraterone and cabazitaxe. ( E4 )
David Gareth Fackrell - University of Birmingham NHS Foundation Trust
Abstract # 235 : Metabolite assay and histology on exactly the same tissue. ( E5 )
Dean A. Troyer - Eastern Virginia Medical School
Abstract # 236 : Experimental therapy of PC-3 and DU-145 human androgen-independent prostate cancers with targeted cytotoxic analog of somatostatin an-162. ( E6 )
Ferenc Rick - Miami VA Medical Center
Abstract # 237 : Testosterone kinetics after proton therapy for low- and intermediate-risk prostate cancer. ( E7 )
Romaine Charles Nichols - University of Florida Proton Therapy Institute
Abstract # 238 : Relationship of overall survival and the frequency of performing transrectal ultrasound-guided biopsy of the prostate in those patients with low-risk tumors electing active surveillance. ( E8 )
David D. Buethe - Moffitt Cancer Center and Research Institute
Abstract # 239 : Generation of virtual control groups for single-arm prostate cancer (PCa) adjuvant trials. ( E9 )
Zhenyu Jia - University of California, Irvine
Abstract # 240 : Age at diagnosis and treatment for prostate cancer (PC) in two distinct integrated healthcare systems. ( E10 )
Deanna S. Cross - Marshfield Clinic Research Foundation
Abstract # 241 : PSA outcomes in patients with adenocarcinoma of the prostate with presenting PSA > 20 ng/ml. ( E11 )
Daniel Shasha - Department of Radiation Oncology, Beth Israel Medical Center
Abstract # 242 : The effects of age, stage, treatment, and Charlson comorbidity index (CCI) on quality of life after prostate cancer diagnosis in a single cohort. ( E12 )
Deanna S. Cross - Marshfield Clinic Research Foundation
Abstract # 243 : Rectal dose-volume differences for scanning proton beam therapy with or without an endorectal balloon for the treatment of prostate cancer. ( E13 )
Anand Desai - Department of Radiation Oncology, The University of Texas MD Anderson Cancer Center
Abstract # 244 : The risk of debilitating falls in Manitobans living with prostate cancer (pc). ( E14 )
Joel Roger Gingerich - CancerCare Manitoba
Abstract # 245 : Biochemical and functional outcomes of brachytherapy for young men (≤50) with prostate cancer. ( E15 )
Daniel Shasha - Department of Radiation Oncology, Beth Israel Medical Center
Abstract # 251 : Progression-free survival as an endpoint for clinical trials in first-line metastatic urothelial cancer. ( E16 )
Matt D. Galsky - Division of Hematology and Medical Oncology, The Tisch Cancer Institute, Mount Sinai School of Medicine
Abstract # 252 : Phase I results from a study of lapatinib with gemcitabine and cisplatin (GC) in advanced/metastatic bladder cancer. ( E17 )
Gedske Daugaard - Rigshospitalet
Abstract # 253 : Evaluation of a novel irreversible pan-HER inhibitor in bladder cancer models. ( E18 )
Petros Grivas - University of Michigan
Abstract # 254 : Association of hospital readmission following cystectomy with omission of postoperative chemotherapy in patients with urothelial carcinoma of the bladder. ( F1 )
Marc C. Smaldone - Fox Chase Cancer Center
Abstract # 255 : Final results of a multicenter, open-label phase II trial of dovitinib (TKI258) in patients with advanced urothelial carcinoma with either mutated or nonmutated FGFR3. ( F2 )
Matthew I. Milowsky - UNC Lineberger Comprehensive Cancer Center
Abstract # 256 : Post-treatment prognostic model for patients (pts) with metastatic urothelial cancer (UC) treated with first-line chemotherapy. ( F3 )
Matt D. Galsky - Division of Hematology and Medical Oncology, The Tisch Cancer Institute, Mount Sinai School of Medicine
Abstract # 257 : Worsening survival of upper tract urothelial carcinoma: A population-based analysis. ( F4 )
Sima P. Porten - The University of Texas MD Anderson Cancer Center
Abstract # 258 : Cost-effectiveness analysis of neoadjuvant chemotherapy in patients with muscle-invasive bladder cancer. ( F5 )
Scott M. Stevenson - Department of Urology, Columbia University College of Physicians & Surgeons
Abstract # 259 : The role of post-cystectomy radiation in treatment of squamous cell carcinoma of the bladder: A combined retrospective analysis. ( F6 )
Baoqing Li - Stich Radiation Oncology Center, Weill Cornell Medical College
Abstract # 260 : Relationship of ERCC1 genotype variant with mRNA expression and ERCC1 protein levels in advanced urothelial carcinoma (UC). ( F7 )
Elizabeth A. Guancial - Lank Center for Genitourinary Oncology, Dana-Farber Cancer Institute
Abstract # 261 : Augmentation of urothelial cancer cells' response to gemcitabine and cisplatin by a Smac mimetic. ( F8 )
Eugene K. Lee - The University of Texas MD Anderson Cancer Center
Abstract # 262 : First-line chemotherapy with gemcitabine, etoposide, and cisplatin in combined-multimodality treatment for patients with advanced urothelial carcinoma. ( F9 )
Shinji Urakami - Department of Urology, Cancer Institute Hospital of Japanese Foundation for Cancer Research
Abstract # 263 : A novel phase I trial design featuring a two-dimensional dose-finding algorithm optimizing the dose of gemcitabine and doxorubicin with bortezomib in metastatic urothelial carcinoma (UC). ( F10 )
Arlene O. Siefker-Radtke - The University of Texas MD Anderson Cancer Center
Abstract # 264 : The role of VEGF/mTOR/AKT pathway in patients with advanced urothelial carcinoma of the bladder cancer. ( F11 )
Rudolf Moritz - Department of Urology, University of Muenster
Abstract # 265 : Long-term outcome of bacilles Calmette-Guerin perfusion therapy for upper urinary tract urothelial carcinoma in situ. ( F12 )
Takahiro Yoneyama - Department of Urology, Hirosaki University Graduate School of Medicine
Abstract # 266 : Sequential chemotherapy with gemcitabine plus carboplatin followed by additional docetaxel for aged patients with advanced bladder cancer. ( F13 )
Takahiro Yoneyama - Department of Urology, Hirosaki University Graduate School of Medicine
Abstract # 267 : Pathologic response rates between gemcitabine-cisplatin (GC) and methotrexate, vinblastine, doxorubicin hydrochloride, and cisplatin (MVAC) neoadjuvant chemotherapy in muscle-invasive urothelial cell carcinoma of the bladder. ( F14 )
Jonathan Lawrence Wright - University of Washington, School of Medicine
Abstract # 268 : The German study group of intravesical hyperthermia-chemotherapy in non-muscle-invasive bladder cancer presents their long-term results in efficacy and tolerability for optimized adjuvant therapy and bladder preservation. ( F15 )
Gerson Lüdecke - University Clinic of Giessen and Marburg GmbH, Giessen
Abstract # 269 : Cisplatin-based combination chemotherapy in elderly patients with metastatic urothelial cancer. ( F16 )
Aristotelis Bamias - HECOG and University of Athens
Abstract # 270 : Different effects of sunitinib, sorafenib, and pazopanib on inducing cancer cell death: The role of autophagy. ( F17 )
Matteo Santoni - Department of Medical Oncology, Polytechnic University of the Marche Region, Azienda Ospedaliero-Universitaria, Ospedali Riuniti Umberto I-GM Lancisi and G Salesi, Ancona, Italy
Abstract # 271 : Phase I/II clinical trial of ALT-801, a T-cell receptor/IL-2 fusion protein, plus gemcitabine and cisplatin in urothelial cancer. ( F18 )
Mayer N. Fishman - H. Lee Moffitt Cancer Center & Research Institute
Abstract # 272 : Cisplatin-associated nephrotoxicity in clinical trials using serum creatinine (SCr) versus calculated glomerular filtration rate (GFR) as inclusion criterion: A meta-analysis. ( G1 )
Arati Dahal - University of Utah School of Medicine
Abstract # 273 : Prediction of survival in patients with muscle-invasive bladder cancer (MIBC) by neutrophil (NTP) infiltration in benign lymph nodes (LNs). ( G2 )
Sumanta Kumar Pal - City of Hope
Abstract # 274 : Reproductive organ involvement in female patients undergoing radical cystectomy. ( G3 )
Hooman Djaladat - Institute of Urology, University of Southern California
Abstract # 275 : Muscle invasive bladder cancer in the elderly: Treatment and prognosis in a prospective cohort study. ( G4 )
Stephanie Slater - School of Cancer Sciences, University of Birmingham
Abstract # 276 : Proportion of elderly patients with advanced bladder cancer receiving cisplatin-based chemotherapy: A large Medicare database study. ( G5 )
Guoqing J. Chen - Michael E. DeBakey VA Medical Center/Baylor College of Medicine
Abstract # 277 : Thromboembolic events with cisplatin-based neoadjuvant chemotherapy for transitional cell carcinoma of urinary bladder. ( G6 )
Joanne Botten - Bristol Haematology and Oncology Centre
Abstract # 278 : A phase II multicenter study of neoadjuvant dose-dense methotrexate, vinblastine, doxorubicin, and cisplatin (ddMVAC) chemotherapy with pegfilgrastim support in patients (pts) muscle-invasive urothelial cancer (MIUC): Safety, pathologic, radiologic, and molecular correlates. ( G7 )
Toni K. Choueiri - Lank Center for Genitourinary Oncology, Dana-Farber Cancer Institute/Brigham and Women's Hospital/Harvard Medical School
Abstract # 279 : Peroxisome proliferator-activated receptor gamma (PPARG) gene amplifications in urothelial carcinoma (UC). ( G8 )
Richard M. Bambury - Memorial Sloan-Kettering Cancer Center and Weill Cornell Medical College
Abstract # 280 : Overexpression of IGF1R to predict outcome in invasive urothelial carcinoma of urinary bladder. ( G9 )
Jenny J. Kim - Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins University
Abstract # 281 : Antioxidant stimulation as the adaptation mechanism in patients with metastatic urothelial cancers (MUC) treated with gemcitabine and cisplatin (GC). ( G10 )
Patrik Palacka - 2nd Oncology Department, School of Medicine, Comenius University and National Cancer Institute
Abstract # 282 : Brain metastases in patients with urothelial carcinoma. ( G11 )
Helen Jane Boyle - Centre Léon Bérard
Abstract # 283 : Radiologic response (RR) by MRI in patients (pts) with muscle-invasive urothelial cancer (MIUC) undergoing neoadjuvant chemotherapy. ( G12 )
Angela Q. Qu - Dana-Farber Cancer Institute
Abstract # 284 : Long-term efficacy and safety outcomes of the modified (simplified) combination of methotrexate, vinblastine, doxorubicin, and cisplatin (MVAC) as front-line therapy for unresectable or metastatic urothelial cancer (UC). ( G13 )
Andrea Necchi - Fondazione IRCCS Istituto Nazionale dei Tumori
Abstract # 285 : A study of genes and microRNAs that may predict clinical responses to anti-CTLA-4 therapy. ( G14 )
Jianjun Gao - The University of Texas MD Anderson Cancer Center
Abstract # 286 : Presence of carcinoma in situ (CIS) in bladder cancer biopsies and its relationship to pathologic complete response (pCR) rates to neoadjuvant chemotherapy (neo-CTx). ( G15 )
Derek E. Thomas - Indiana University Simon Cancer Center
Abstract # 287 : Bladder cancer: Predicting response to BCG. ( G16 )
Rafael Nunez-Nateras - Mayo Clinic
Abstract # 288 : Correlation of abnormal upper tract cytology and tumor histology in patients who have undergone a nephroureterectomy for urothelial carcinoma with disease recurrence in the bladder. ( G17 )
Einar Freyr Sverrisson - Genitourinary Oncology Program, H. Lee Moffitt Cancer Center & Research Institute
Abstract # 290 : Prediction of pathologic complete response to neoadjuvant chemotherapy in urothelial cancer by genetic determinants of platinum sensitivity. ( H1 )
Peter H. O'Donnell - The University of Chicago
Abstract # 291 : Association of persistent, unexplained leukocytosis, a paraneoplastic syndrome, with poor prognosis in patients with urothelial carcinoma of the bladder. ( H2 )
Jason Patrick Izard - University of Washington
Abstract # 292 : HER2 expression in patients (pts) with surgically resected urothelial cancer at high risk of recurrence screened for the phase II randomized, open-label trial of DN24-02, an autologous cellular immunotherapy targeting HER2. ( H3 )
Michael F. Press - University of Southern California Norris Comprehensive Cancer Center
Abstract # 293 : CEP-11981, a small molecule inhibitor of multiple angiogenic targets, in a preclinical system of urothelial carcinoma (UC). ( H4 )
Weiguo Jian - Baylor College of Medicine
Abstract # 294 : The preclinical anti-angiogenic and pro-apoptotic activity of lenalidomide in urothelial carcinoma (UC). ( H5 )
Weiguo Jian - Baylor College of Medicine
Abstract # 295 : Presence of variant histology (VarHst) in transurethral resection of bladder tumor (TURBT) biopsies and its prognostic significance on pathologic complete response (pCR) rates to neoadjuvant chemotherapy (neo-CTx). ( H6 )
Jose Alexandre Pedrosa - Indiana University Department of Urology and Simon Cancer Center
Abstract # 296 : Effectiveness and safety of valrubicin in non–muscle-invasive bladder cancer following reintroduction: Results from a medical chart review study. ( H7 )
Michael S. Cookson - Vanderbilt University Medical Center
Abstract # 297 : Current management and proposal for guidance of radiation cystitis (RC): Results of a British Uro-oncology Group (BUG) survey. ( H8 )
Amit K. Bahl - University Hospitals Bristol
Abstract # 298 : Tumor burden reduction in an orthotopic non-muscle-invasive bladder cancer model using IL-15 analogue (ALT-803) targeting T regulatory cells. ( H9 )
Evan Gomes - MD Anderson Cancer Center Orlando
Abstract # 299 : Using micro-RNA expression to predict response to neoadjuvant chemotherapy in urothelial carcinoma of the bladder. ( H10 )
Raya Leibowitz-Amit - Princess Margaret Hospital
Abstract # 300 : Exome sequencing of extreme phenotypes to identify variants predictive of response to chemotherapy in bladder cancer. ( H11 )
Shaheen Alanee - Memorial Sloan-Kettering Cancer Center
Abstract # 301 : Impact of baseline prognostic factors on progression-free survival at 6 months (PFS6) and response in patients receiving second-line therapy for advanced urothelial carcinoma (UC). ( H12 )
Guru Sonpavde - University of Alabama at Birmingham (First Author: Gregory Russell Pond - McMaster University)
Abstract # 302 : Discovery of molecular biomarker signatures for the detection of bladder cancer. ( H13 )
Evan Gomes - MD Anderson Cancer Center Orlando
Abstract # 303 : Pre-cystectomy serum levels of CA19-9, CA125, and CEA: Correlation with pathologic stage and oncologic outcome in urothelial carcinoma of bladder. ( H14 )
Hamed Ahmadi - USC Institute of Urology, USC/Norris Comprehensive Cancer Center
Abstract # 304 : Combining next-gen sequencing of TP53 and FGFR3 for detecting bladder cancer-related mutations. ( H15 )
John M. Millholland - Predictive Biosciences
Abstract # 305 : DNA repair capacity and tumor recurrence in patients with non-muscle-invasive bladder cancer (NMIBC). ( H16 )
Timothy F. Donahue - Department of Surgery, Sidney Kimmel Center for Prostate and Urologic Cancers, Memorial Sloan-Kettering Cancer Center, New York, NY
Abstract # 306 : A multi-analyte assay for the noninvasive detection of bladder cancer. ( H17 )
Makito Miyake - MD Anderson Cancer Center Orlando
Abstract # 307 : Paragangliomas of the urinary bladder: Experience at the National Cancer Institute. ( H18 )
Michael Weintraub - Urologic Oncology Branch, National Cancer Institute
Abstract # 308 : Management of cT1 micropapillary bladder cancer. ( J1 )
Daniel Levi Willis - The University of Texas MD Anderson Cancer Center
Abstract # 309 : Efficacy and safety of valrubicin in non–muscle-invasive bladder cancer in older and younger patients. ( J2 )
Michael S. Cookson - Vanderbilt University Medical Center
Abstract # 310 : Selective organ preservation with neoadjuvant chemotherapy in the treatment of muscle invasive transitional cell carcinoma (TCC) of the bladder. ( J3 )
Shaista Hafeez - The Royal Marsden NHS Foundation Trust
Abstract # 311 : Survival outcomes in patients undergoing neoadjuvant chemotherapy for upper tract urothelial cell carcinoma. ( J4 )
Sima P. Porten - The University of Texas MD Anderson Cancer Center
Abstract # 312 : Contemporary evaluation of urography in diagnosis in patients with urothelial cell carcinoma. ( J5 )
Anna Maria Leliveld - University Medical Center Groningen
Abstract # 313 : A comparison of toxicity of gemcitabine versus platinum-based combined chemoradiation for muscle-invasive bladder cancer: The Memorial Sloan-Kettering experience. ( J6 )
Sujith Baliga - Albert Einstein College of Medicine
Abstract # 314 : Preclinical and correlative studies of cabozantinib (XL184) in urothelial cancer (UC). ( J7 )
Andrea Borghese Apolo - National Cancer Institute
Abstract # 315 : Low-grade micropapillary urothelial carcinoma: Does it exist? A SEER analysis of management and outcomes. ( J8 )
Srinivas Vourganti - Urologic Oncology Branch, National Cancer Institute
Abstract # 316 : Perioperative management of radical cystectomy patients: A questionnaire survey of the American Urological Association members. ( J9 )
Hong Truong - Urologic Oncology Branch, National Cancer Institute
Abstract # 317 : Clinical outcomes in focal versus extensive micropapillary bladder cancer at the time of diagnostic transurethral resection. ( J10 )
Daniel Levi Willis - The University of Texas MD Anderson Cancer Center
Abstract # 318 : Outcome of patients with micropapillary bladder cancer treated with neoadjuvant therapy and radical cystectomy. ( J11 )
Daniel Levi Willis - The University of Texas MD Anderson Cancer Center
Abstract # 321 : Neoadjuvant carboplatin in stage IIa and IIb seminoma. ( J12 )
Alan Horwich - The Institute of Cancer Research and The Royal Marsden NHS Foundation Trust
Abstract # 322 : Preoperative intensity modulated radiation therapy for retroperitoneal sarcoma. ( J13 )
Nancy El Bared - University of Montreal
Abstract # 323 : Is there an intermediate risk group of nonseminoma? ( J14 )
Jaroslav Hajek - University Hospital, Oncology
Abstract # 324 : A meta-analysis of patient outcomes with subcentimeter disease after chemotherapy for metastatic nonseminomatous germ cell tumor (NSGCT). ( J15 )
Elizabeth O'Donnell - Dana-Farber Cancer Institute
Abstract # 325 : A 10-year retrospective review of germ cell tumors not cured with cisplatin-based chemotherapy. ( J16 )
Elizabeth O'Donnell - Dana-Farber Cancer Institute
Abstract # 326 : Inguinal lymph node dissection for penile carcinoma: Postoperative complications using a validated classification system. ( K1 )
Isuru Sampath Jayaratna - University of Southern California Institute of Urology
Abstract # 327 : Antitumor activity of brentuximab vedotin in CD30 positive refractory germ cell tumors. ( K2 )
Costantine Albany - Indiana University Melvin and Bren Simon Cancer Center
Abstract # 328 : Modified cisplatin, etoposide, and ifosfamide (PEI) salvage therapy for male germ-cell tumors (GCT): Long-term efficacy and safety outcomes. ( K3 )
Andrea Necchi - Fondazione IRCCS Istituto Nazionale dei Tumori
Abstract # 329 : Persistence of CD30 expression by embryonal carcinoma (EC) in the treatment time course: A retrospective series of multirelapsing germ cell tumors (GCT). ( K4 )
Patrizia Giannatempo - Fondazione IRCCS Istituto Nazionale dei Tumori
Abstract # 330 : The development of a validated data linked tissue microarray of bladder cancer patients undergoing cystectomy. ( K5 )
Richard Robinson - University of Manchester
Abstract # 331 : Postchemotherapy retroperitoneal lymph node dissection for advanced germ cell tumors at a Japanese single high-volume center. ( K6 )
Terukazu Nakamura - Department of Urology, Kyoto Prefectural University of Medicine
Abstract # 332 : Treatment patterns for patients with localized (T1-T2) penile squamous cell carcinoma in the United States. ( K7 )
Brittney Diane Barbosa - The University of North Carolina at Chapel Hill
Abstract # 333 : Surface applicator high-dose-rate fractionated brachytherapy for conservative definitive management of extramammilary Paget’s disease of the penis, scrotum, and mons pubis. ( K8 )
Phillip M. Devlin - Dana-Farber Cancer Institute/Brigham and Women's Hospital, Harvard Medical School
Abstract # 334 : Long-term survival rates after chemotherapy (CTx) in patients (pts) with nonseminomatous (NS) germ cell tumors (GCT) with teratoma (T). ( K9 )
Sujata Patil - Memorial Sloan-Kettering Cancer Center
Abstract # 335 : Use of radiotherapy for seminoma patients with low-volume infradiaphragmatic nodal disease. ( K10 )
Swetha Sridharan - Princess Margaret Hospital
Abstract # 336 : Phase II trial of paclitaxel, ifosfamide, and cisplatin (TIP) for previously untreated patients (pts) with intermediate- or poor-risk germ cell tumors (GCT). ( K11 )
Darren Richard Feldman - Memorial Sloan-Kettering Cancer Center
Abstract # 337 : Survivorship care in Canadian genitourinary oncology: Toward a multidisciplinary perspective. ( K12 )
Sue Richter - Princess Margaret Hospital
Abstract # 338 : Long-term outcomes of cisplatin-based chemotherapy in patients with stage II-III germ cell tumors: Center 30-year experience of a single-center. ( K13 )
Guillermo De Velasco - Medical Oncology Service, Hospital Universitario 12 de Octubre
Abstract # 339 : The increasing incidence of testicular cancer in the United States from 1992 to 2009. ( K14 )
Manas Nigam - University of Chicago Pritzker School of Medicine
Abstract # 340 : Treatment of metastatic penile cancer in the adjuvant setting with ifosfamide, paclitaxel, and cisplatin: A single institution experience. ( K15 )
Aine O'Reilly - Mercy University Hospital
General Poster Session C: Renal Cell Cancer
Abstract # 347 : Incidence and risk of treatment-related mortality in patients with renal cell cancer (RCC) and non-RCC treated with mammalian target of rapamycin (mTOR) inhibitors. ( A1 )
Toni K. Choueiri - Dana-Farber Cancer Institute/Harvard Medical School
Abstract # 343 : Surveillance for the management of small renal masses: Utilization and outcomes in a population-based cohort. ( A2 )
William C. Huang - NYU School of Medicine
Abstract # 344 : Outcomes, complications, and costs of care of Bosniak IIF, III, and IV cystic renal lesions/malignancies: Data from the largest multi-institutional study to date. ( A3 )
Andrew D. Smith Department of Radiology, University of Mississippi Medical Center
Abstract # LBA348 : Axitinib versus sorafenib as first‑line therapy in patients with metastatic renal cell carcinoma (mRCC) ( A4 )
Thomas Hutson - Baylor Charles A. Sammons Cancer Center and US Oncology Research
Abstract # 345 : The best trial (E2804): A randomized phase II study of VEGF, RAF kinase, and mTor combination targeted therapy (CTT) with bevacizumab (bev), sorafenib (sor), and temsirolimus (tem) in advanced renal cell carcinoma (RCC). ( A5 )
David F. McDermott - Beth Israel Deaconess Medical Center
Abstract # 342 : Defining early-onset kidney cancer: Implications for genetic counseling. ( A6 )
Brian Shuch - Urologic Oncology Branch, National Cancer Institute
Abstract # 341 : Toward a molecular genetic classification of clear cell renal cell carcinoma. ( A7 )
James Brugarolas - The University of Texas Southwestern Medical Center
Abstract # 346 : Quality of life (QoL) among patients with renal cell carcinoma (RCC) treated with pazopanib versus sunitinib in the COMPARZ study. ( B1 )
David Cella - Feinberg School of Medicine, Northwestern University
Abstract # LBA 349 : Axitinib with or without dose titration for first-line metastatic renal cell carcinoma (mRCC): Unblinded results from a randomized phase II study. ( B2 )
Brian Rini - Cleveland Clinic Taussig Cancer Institute
Abstract # 350 : Overall survival results from a phase III study of tivozanib hydrochloride versus sorafenib in patients with renal cell carcinoma. ( B3 )
Robert John Motzer - Memorial Sloan-Kettering Cancer Center
Abstract # 351 : Clinical activity and safety of antiprogrammed death-1 (PD-1) (BMS-936558/MDX-1106/ONO-4538) in patients (pts) with previously treated, metastatic renal cell carcinoma (mRCC): An updated analysis. ( B4 )
David F. McDermott - Beth Israel Deaconess Medical Center
Abstract # 352 : Relationship between biomarkers and everolimus efficacy in the phase III record-1 trial of patients with metastatic renal cell carcinoma (mRCC). ( B5 )
Stephane Oudard - Oncology Translational Research Unit, Georges Pompidou Hospital
Abstract # 353 : Incidence and risk of infections in renal cell cancer (RCC) and non-RCC patients treated with everolimus and temsirolimus: A meta-analysis of randomized control trials. ( B6 )
Marina Kaymakcalan - Dana-Farber Cancer Institute
Abstract # 354 : Subgroup analyses of a phase III trial comparing tivozanib hydrochloride versus sorafenib as initial targeted therapy for patients (pts) with metastatic renal cell carcinoma (mRCC). ( B7 )
Thomas E. Hutson - Texas Oncology–Baylor Charles A. Sammons Cancer Center
Abstract # 355 : Treatment benefit of tivozanib hydrochloride versus sorafenib on health-related quality of life (HRQoL) among patients (pts) with advanced/metastatic renal cell carcinoma (mRCC): Tivo-1 study results. ( B8 )
David Cella - Northwestern University
Abstract # 356 : Overall survival (OS) of sorafenib (So) plus interleukin-2 (IL-2) versus So alone in patients with treatment-naive metastatic renal cell carcinoma (mRCC): Final update of the ROSORC trial. ( B9 )
Giuseppe Procopio - Fondazione IRCCS Istituto Nazionale dei Tumori
Abstract # 357 : Prolonged survival with personalized immunotherapy (AGS-003) in combination with sunitinib in unfavorable risk metastatic RCC (mRCC). ( B10 )
Asim Amin - Carolinas Medical Center
Abstract # 358 : A phase Ib clinical trial of the multitargeted kinase inhibitor lenvatinib (E7080) in combination with everolimus for treatment of metastatic renal cell carcinoma (RCC). ( B11 )
Ana M. Molina - Memorial Sloan-Kettering Cancer Center
Abstract # 359 : Outcomes of patients with sarcomatoid renal cell carcinoma: The Mayo Clinic experience. ( B12 )
Brian Addis Costello - Mayo Clinic
Abstract # 360 : Association of mutations in chromatin modifiers with poor survival in clear cell renal cell carcinoma: Analysis of the Cancer Genome Atlas Project. ( B13 )
A. Ari Hakimi - Memorial Sloan-Kettering Cancer Center
Abstract # 361 : Relationship of hypoxia signature with variant subgroup of clear cell renal cell carcinoma (ccRCC) and its association with clinical activity on tivozanib hydrochloride. ( B14 )
Murray Owen Robinson - AVEO Oncology
Abstract # 362 : Pulmonary complications with the use of mTOR inhibitors in targeted cancer therapy: A systematic review and meta-analysis. ( B15 )
Benjamin Adam Gartrell - Division of Oncology, Montefiore Medical Center
Abstract # 363 : Significant adverse health outcomes are associated with both partial and radical nephrectomy: Is It time to re-assess the “Gold Standard” for the small renal mass? ( B16 )
Brian Shuch - Urologic Oncology Branch, National Cancer Institute
Abstract # 364 : Efficacy and safety data from patients with advanced renal cell cancer treated with tivozanib hydrochloride after progression on sorafenib. ( C1 )
Robert John Motzer - Memorial Sloan-Kettering Cancer Center
Abstract # 365 : Ten-year follow up of patients (pts) with metastatic renal cell carcinoma (mRCC) treated with interferon alfa-2b (IFN) as first-line therapy: Results from a randomized trial. ( C2 )
Henry Jacob Conter - Division of Cancer Medicine, The University of Texas MD Anderson Cancer Center
Abstract # 366 : Comparison of PFS and safety for Asian compared to North American and European populations in the phase III trial of pazopanib versus sunitinib in patients with treatment-naive RCC (COMPARZ). ( C3 )
Jun Guo - Peking University Cancer Hospital
Abstract # 367 : Outcomes of patients (pts) with metastatic renal cell carcinoma (mRCC) treated with pazopanib after progression on other targeted therapies (TT): Updated results. ( C4 )
Marc Ryan Matrana - The University of Texas MD Anderson Cancer Center
Abstract # 368 : SGN-75 in the treatment of patients with CD70-positive malignancies including metastatic renal cell carcinoma. ( C5 )
John A. Thompson - Seattle Cancer Care Alliance
Abstract # 369 : Phase I study of high-dose interleukin 2, aldesleukin, in combination with the histone deacetylase inhibitor, entinostat, in patients with metastatic renal cell carcinoma: Safety and tolerability results. ( C6 )
Roberto Pili - Roswell Park Cancer Institute
Abstract # 370 : Inhibition of tumor growth in a VEGFR TKI-resistant model of renal cell carcinoma using dalantercept combined with sunitinib. ( C7 )
Rupal Satish Bhatt - Beth Israel Deaconess Medical Center
Abstract # 371 : Using presurgical sunitinib to select patients with newly diagnosed metastatic clear cell renal cell carcinoma for cytoreductive nephrectomy: A phase II study.^ ( C8 )
Eric Jonasch - The University of Texas MD Anderson Cancer Center
Abstract # 372 : Novel stratification of the recurrence risk following surgical extirpation of clear cell renal cell carcinoma using tissue biomarkers in the mammalian target of rapamycin pathway. ( C9 )
Oussama M. Darwish - The University of Texas Southwestern Medical Center
Abstract # 373 : Meta-analysis of hematologic toxicities in patients with cancer treated with sunitinib. ( C10 )
Tomohiro Funakoshi - Beth Israel Medical Center
Abstract # 374 : Significance of zoledronic acid on survival in patients with bone metastases from renal cell carcinoma. ( C11 )
Yosuke Yasuda - Cancer Institute Hospital
Abstract # 375 : MicroRNA as novel blood-based biomarkers in clear cell renal cell carcinoma. ( C12 )
A. Ari Hakimi - Memorial Sloan-Kettering Cancer Center
Abstract # 376 : Risk of hypothyroidism in patients with cancer treated with sunitinib: A systematic review and meta-analysis. ( C13 )
Tomohiro Funakoshi - Beth Israel Medical Center
Abstract # 377 : Prognostic significance of indeterminate lung nodules in renal cell carcinoma. ( C14 )
Rena Xu - Harvard Medical School
Abstract # 378 : Contrasting the vascular response to sunitinib as measured by DCE-CT, DCE-MRI, and DCE-US. ( C15 )
John M. Hudson - Department of Medical Biophysics, University of Toronto
Abstract # 379 : Global metabolic profiling of clear cell renal cell carcinoma. ( C16 )
A. Ari Hakimi - Memorial Sloan-Kettering Cancer Center
Abstract # 380 : Development and internal validation of a prognostic nomogram for overall survival in patients with advanced renal cell carcinoma (aRCC) treated with pazopanib (PAZ). ( D1 )
Michael W. Kattan - Cleveland Clinic Quantitative Health Sciences
Abstract # 381 : A single-center retrospective review of outcomes associated with sunitinib alternative schedule compared to traditional schedule. ( D2 )
Bradley J. Atkinson - The University of Texas MD Anderson Cancer Center
Abstract # 382 : Multiplexed tissue protein assay to predict patient response to targeted therapy in advanced renal cell carcinoma. ( D3 )
Ulka N. Vaishampayan - Wayne State University
Abstract # 383 : Clinical evaluation of 2-(18F) fluoro-2 deoxy-d-glucose PET/ CT in hereditary leiomyomatosis and renal cell carcinoma. ( D4 )
Brian Shuch - Urologic Oncology Branch, National Cancer Institute
Abstract # 384 : Increase in blood pressure with sorafenib exposure in renal cell carcinoma versus other solid tumors. ( D5 )
Amishi Shah - University of Pennsylvania
Abstract # 385 : Supression of tumor progression and metastasis in renal cell carcinoma by mir-192, mir-194, and mir-215. ( D6 )
George M. Yousef - Department of Laboratory Medicine and Keenan Research (First Author: Heba W.Z. Khella - Department of Laboratory Medicine and Keenan Research Centre, St. Michael's Hospital)
Abstract # 386 : The role of FGF signaling in VEGF-pathway targeted therapy resistance: Data from patients and model systems. ( D7 )
Thai Huu Ho - Mayo Clinic
Abstract # 387 : Investigating the association of cytoplasmic and nuclear HIF-2 expression with cancer specific survival (CSS) in clear cell renal cell carcinoma. ( D8 )
Nils Kroeger - Institute of Urologic Oncology, Department of Urology, UCLA
Abstract # 388 : Effect of VEGF and VEGFR polymorphisms on clinical outcome and response in patients with advanced renal cell carcinoma receiving first-line treatment. ( D9 )
Maristella Bianconi - Scuola di Specializzazione in Oncologia Medica, Università Politecnica delle Marche
Abstract # 389 : The targeted therapy reduced the risk of rapid progression and early death in renal cell carcinoma. ( D10 )
Shenhong Wu - Stony Brook Medicine
Abstract # 390 : Real-world treatment patterns in third-line patients with metastatic renal cell carcinoma (mRCC): The changing landscape in the United States. ( D11 )
Sumanta Kumar Pal - City of Hope
Abstract # 391 : Treatment outcome with mTOR inhibitors for 65 cases of non-clear cell renal cell carcinoma: Association of long-term responses and oncogenomic events. ( D12 )
Martin Henner Voss - Memorial Sloan-Kettering Cancer Center
Abstract # 392 : Everolimus for patients with metastatic renal cell carcinoma (mRCC) refractory to anti-VEGF therapy: Preliminary results of a pooled analysis of noninterventional studies. ( D13 )
Laurence Albiges - Department of Medical Oncology, Institut Gustave Roussy
Abstract # 393 : Impact of chromosomal copy number variation on outcome in metastatic clear cell renal cell carcinoma patients treated with antiangiogenic agents. ( D14 )
Eric Jonasch - The University of Texas MD Anderson Cancer Center
Abstract # 394 : Impact of bone and liver metastases (BM, LM) in patients with metastatic renal cell carcinoma (mRCC) treated with molecularly targeted agents (MTAs): Results from the International mRCC Database Consortium (IMDC). ( D15 )
Rana R. McKay - Dana-Farber Cancer Institute
Abstract # 395 : Analysis of molecular profiling of renal cell carcinoma: Identification of a 4-microRNA signature as a prognostic value in patients with stage I-II disease. ( D16 )
Daniel E. Castellano - Uro-Oncology Unit, 12 de Octubre Universitary Hospital
Abstract # 396 : Metastatic non–clear cell renal cell carcinoma (nccRCC) treated with targeted therapy agents: Applying the International Metastatic Renal Cell Carcinoma Database Consortium (IMDC) prognostic model to predict outcomes. ( E1 )
Nils Kroeger - Tom Baker Cancer Centre
Abstract # 397 : Updated phase I results of a phase I/II trial of BNC105P with everolimus in patients with metastatic renal cell carcinoma (mRCC). ( E2 )
Thomas E. Hutson - US Oncology Research, McKesson Specialty Health, The Woodlands, TX, and Baylor Charles A. Sammons Cancer Center-Texas Oncology PA
Abstract # 398 : Metabolic complications with the use of mTOR inhibitors for cancer therapy: A systematic review and meta-analysis. ( E3 )
Shanthi Sivendran - Hematology/Oncology Medical Specialists, Lancaster General Health
Abstract # 399 : Could a biomarkers-based patients' selection help to plan a clinical trial with targeted agents (TA) for metastatic renal cell carcinoma (mRCC)? Interaction and power analysis of randomized trials (RCTs). ( E4 )
Francesco Massari - Medical Oncology
Abstract # 400 : Real-life patterns of use and effectiveness of sunitinib in patients with metastatic renal cell carcinoma: The SANTORIN study. ( E5 )
Alain Ravaud - CHU de Bordeaux, INSERM CIC-P0005
Abstract # 401 : Characteristics and clinical outcomes of patients with renal cell carcinoma with sarcomatoid dedifferentiation (sRCC). ( E6 )
Megan M. Merrill - The University of Texas MD Anderson Cancer Center
Abstract # 402 : RAD001 and zoledronic acid in patients with renal cell carcinoma with bone metastases (RAZOR): A randomized phase II trial. ( E7 )
Reuben James Broom - Auckland City Hospital
Abstract # 403 : Genetic polymorphisms and sunitinib outcome in metastatic renal-cell carcinoma: A prospective observational study and validation. ( E8 )
Carlos A. Farfán - Uro-Oncology Unit, 12 de Octubre Universitary Hospital
Abstract # 404 : Prognostic role of cell cycle–related biomarkers in clear cell renal cell carcinoma. ( E9 )
Bishoy A. Gayed - The University of Texas Southwestern Medical Center
Abstract # 405 : Plasma MN (carbonic anhydrase IX) and outcome in sunitinib-treated metastatic renal cell cancer. ( E10 )
Nicholas E. Lamparella - Penn State Hershey Cancer Institute, Penn State Milton S. Hershey Medical Center
Abstract # 406 : Association of a 2-weeks-on and 1-week-off schedule of sunitinib with decreased toxicity in metastatic renal cell carcinoma. ( E11 )
Yana George Najjar - Cleveland Clinic Foundation
Abstract # 407 : Predicting survival in metastatic RCC on sunitinib using MASS criteria: Evaluation of a large multicentered prospective phase III trial. ( E12 )
Andrew D. Smith - Department of Radiology, University of Mississippi Medical Center
Abstract # 408 : Association of partial nephrectomy with a long-term survival advantage in patients between age 20 and 44 with renal cell carcinomas ≤ 4 cm: An analysis of the SEER database. ( E13 )
Michael R. Daugherty - SUNY Upstate Medical University
Abstract # 409 : Tumor thrombus transection in renal cell carcinoma. ( E14 )
Joseph C. Klink - Glickman Urological & Kidney Institute, Cleveland Clinic
Abstract # 410 : Validation of the pretreatment neutrophil-lymphocyte ratio as prognostic factor regarding cancer-specific, metastasis-free, and overall survival in a European cohort of patients with renal cell carcinoma. ( E15 )
Georg C. Hutterer - Department of Urology, Medical University of Graz
Abstract # 411 : Discovery and validation of the nuclear export protein CRM1 (XPO1) as a new target for the treatment of renal cell carcinoma (rcc). ( F2 )
Hiromi Inoue Wettersten - University of California, Davis
Abstract # 412 : Relative quantification of protein expression in metastatic renal cell carcinoma using iTRAQ LC-MS/MS analysis reveals galectin-1 as a potential prognostic marker and therapeutic target. ( F3 )
Nicole M.A. White - Department of Laboratory Medicine and the Keenan Research Centre in the Li Ka Shing Knowledge Institute of St. Michael’s Hospital
Abstract # 413 : Effect of PD-0332991, a potent and selective inhibitor of cyclin-dependent kinase 4/6, on proliferation in renal cell carcinoma at nanomolar concentrations and prediction of sensitivity by molecular markers. ( F4 )
Joshua E. Logan - Institute of Urologic Oncology, Department of Urology, UCLA
Abstract # 414 : CpG island hypermethylation of corticotropin-releasing hormone-binding protein in kidney cancer and association with clinicopathological parameters. ( F5 )
Hossein Tezval - Hannover Medical School
Abstract # 415 : Retrospective analysis of sorafenib as first- or second- target therapy in patients with mRCC: Three-year italian experience. ( F6 )
Giuseppe Procopio - Fondazione IRCCS Istituto Nazionale dei Tumori
Abstract # 416 : B7H1 expression and association with clinical response to sunitinib therapy in patients with metastatic renal cell carcinoma (mRCC). ( F7 )
Jenny J. Kim - Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins University
Abstract # 417 : Induction of immunogenicity after irradiation of renal carcinoma cell lines. ( F8 )
Gregory Janda - Buffalo State, State University of New York
Abstract # 418 : Sequential use of targeted therapies for metastatic renal cell carcinoma: A physician survey and chart review of community oncology practices in the United States. ( F9 )
Nicholas J. Vogelzang - US Oncology Research/Comprehensive Cancer Centers of Nevada
Abstract # 419 : Comparision of histologic distribution of RCC in young and older patients: Results from the SEER database. ( F10 )
Michael R. Daugherty - SUNY Upstate Medical University
Abstract # 420 : Interstitial lung diseases during treatment with sunitinib or mTOR inhibitors in metastatic renal cell carcinoma. ( F11 )
Philipp Ivanyi - Department of Hematology, Hemostasis, Oncology, and Stem Cell Transplantation, Hannover Medical School
Abstract # 421 : Defining the molecular tumor margin regions of clear cell renal carcinoma tissues by MALDI-MS imaging of lipid and glycan species. ( F12 )
Richard Drake - Medical University of South Carolina
Abstract # 422 : Survival trends among patients with advanced renal cell carcinoma (RCC) in the United States. ( F13 )
Binay Kumar Shah - Saint Joseph Regional Medical Center
Abstract # 423 : Tumor shrinkage during VEGF inhibitor therapy as an independent predictor of PFS and OS in renal cell carcinoma (RCC). ( F14 )
Viktor Gruenwald - Department of Hematology, Hemostasis, Oncology, and Stem Cell Transplantation, Hannover Medical School
Abstract # 424 : Outcomes of second-targeted therapy for mRCC: A retrospective chart review of community practices in the United States. ( F15 )
Eric Jonasch - The University of Texas MD Anderson Cancer Center
Abstract # 425 : Prognostic impact of baseline serum C-reactive protein in metastatic renal cell carcinoma treated with sunitinib. ( F16 )
Vano Yann-Alexandre - Department of Medical Oncology, Georges Pompidou European Hospital, Assistance Publique - Hôpitaux de Paris, Paris-5 René Descartes University
Abstract # 426 : Hypertension and myelosuppression as biomarkers of sunitinib efficacy in Chinese patients (pts) with metastatic renal cell carcinoma (mRCC). ( G1 )
Shukui Qin - PLA Cancer Center of Nanjing Bayi Hospital
Abstract # 427 : Incidence and outcome of interstitial lung disease (ILD) with everolimus treatment for metastatic renal cell carcinoma. ( G2 )
Fumiya Hongo - Department of Urology, Kyoto Prefectural University of Medicine
Abstract # 428 : ER stress protein, GRP78, as a therapeutic target combined with antiangiogenic therapy in renal cell carcinoma. ( G3 )
Kyung Seok Han - Department of Urology and Urological Science Institute, Yonsei University College of Medicine
Abstract # 429 : Immune cell repertoire in patients with indolent metastatic renal cell carcinoma. ( G4 )
Hui Zhu - Cleveland Clinic Taussig Cancer Institute
Abstract # 430 : First-line mTOR inhibition in metastatic renal cell carcinoma (mRCC): An analysis from the International mRCC Database Consortium. ( G5 )
Lauren Christine Harshman - Dana-Farber Cancer Institute
Abstract # 431 : Progression-free survival (PFS) and overall survival (OS) in patients receiving three targeted therapies (TTs) for metastatic renal cell carcinoma (mRCC). ( G6 )
Elena Verzoni - Fondazione IRCCS Istituto Nazionale dei Tumori
Abstract # 432 : Nano-scale proteomic profiling to define diagnostic signatures and biomarkers of therapeutic activity in patients with RCC. ( G7 )
Alice C. Fan - Stanford University School of Medicine
Abstract # 433 : Outcomes of RCC patients with venous thrombus presenting with pulmonary embolism: A multicenter analysis of 782 consecutive patients. ( G8 )
Edwin Jason Abel - University of Wisconsin
Abstract # 434 : A pharmacodynamic trial of sequential sunitinib (Su) with bevacizumab (Bev) in patients (Pts) with renal cell carcinoma and other advanced solid malignancies. ( G9 )
Justine Yang Bruce - University of Wisconsin Carbone Cancer Center
Abstract # 435 : Prediction of systemic spread independent of local extension or nodal disease by venous tumor thrombus in renal cell carcinoma. ( G10 )
Ahmed Aboumohamed - Roswell Park Cancer Institute
Abstract # 436 : Prospective assessment of circulating endothelial cells (CECs) as early markers of clear cell renal cell carcinoma (CCRCC) progression in first-line setting: The Circles study (SOGUG 2011-01). ( G11 )
Victor Oyarvides - Centro Universitario Contra el Cáncer de la Universidad Autónoma de Nuevo León
Abstract # 437 : Dynamic molecular changes with VEGF targeted therapy in metastatic clear cell renal cancer. ( G12 )
Thomas Powles - Barts Cancer Institute
Abstract # 438 : Relationship of aberrant glycosylation of n-glycan on immunoglobulins with survival of patients with renal cell carcinoma. ( G13 )
Shingo Hatakeyama - Department of Urology, Hirosaki University Graduate School of Medicine
Abstract # 439 : The risk of proteinuria with the angiogenesis inhibitor axitinib in patients with cancer. ( G14 )
Andrew Kuei - Stony Brook Medicine
Abstract # 440 : Partial nephrectomy in the setting of metastatic renal cell carcinoma. ( G15 )
Kara Babaian - The University of Texas MD Anderson Cancer Center
Abstract # 441 : A comparison of outcomes regarding robotic versus open partial nephrectomy. ( G16 )
Zachary Adam Hamilton - University of Kansas
Abstract # 442 : Outcomes for a multi-institutional cohort of patients treated with intra-operative radiation therapy for advanced or recurrent renal cell carcinoma. ( H1 )
Jonathan J. Paly - Massachusetts General Hospital
Abstract # 443 : Sunitinib-associated hypothyroidism in patients with metastatic renal cell carcinoma. ( H2 )
Satinder Jagdev - St Jame's Institute of Oncology
Abstract # 444 : Outcome of active surveillance prior to systemic target therapy in patients with metastatic renal cell carcinoma. ( H3 )
Nobuaki Matsubara - National Cancer Center Hospital East
Abstract # 445 : Patient and physician perspective on published therapy management recommendations for TKI-treated patients with a focus on sunitinib: The themapac project (Therapy Management Patient Consensus). ( H4 )
Berit Eberhardt-Wetherington - Das Lebenshaus e.V.
Abstract # 446 : Association of topoisomerase II expression and cancer-specific death in patients with surgically resected clear cell renal cell carcinoma. ( H5 )
Faithlore Gardner - Mayo Clinic
Abstract # 447 : Association of CTCAE v4 grading of hypertension with toxicity in patients with renal cancer receiving vascular endothelial growth factor (VEGF)-targeting agents. ( H6 )
Naveed Hassan Akhtar - Weill Cornell Medical College
Abstract # 448 : Molecular expression profiling and pathway analysis of formalin-fixed paraffin-embedded primary renal tumor specimens. ( H7 )
Luis M. Antón Aparicio - A Coruña University Hospital
Abstract # 449 : Association of renal cell carcinoma and hematologic malignancy. ( H8 )
Leticia Varella - St Luke's-Roosevelt Hospital Center
Abstract # 450 : mTOR inhibitor therapy for metastatic sarcomatoid clear cell renal cell carcinoma (ccRCC). ( H9 )
Diogo Assed Bastos - Memorial Sloan-Kettering Cancer Center
Abstract # 451 : Preoperative C-reactive protein combined with SSIGN score as an independent predictor of cancer-specific survival in patients with clear cell renal cell carcinoma. ( H10 )
Lindsey Allison Herrel - Emory University
Abstract # 452 : High-dose bolus interleukin-2: Correlating response rate with number of doses received. ( H11 )
Jolly Patel - H. Lee Moffitt Cancer Center & Research Institute
Abstract # 453 : Is there a "trial effect" on outcome of patients with metastatic renal cell carcinoma (mRCC) treated with sunitinib? ( H12 )
Daniel Keizman - Genitourinary Oncology Service, Division of Oncology, Meir Medical Center, Sackler School of Medicine, Tel Aviv University
Abstract # 454 : Body mass index and survival of patients with metastastic renal cell carcinoma: Data from the German prospective RCC registry. ( H13 )
Lothar Mueller - Onkologische Schwerpunktpraxis Leer-Emden
Abstract # 455 : Effect of pazopanib on myeloid-derived suppressor cells and T-cell function in patients with metastatic renal cell carcinoma. ( H14 )
Kiranpreet K. Khurana - Cleveland Clinic
Abstract # 456 : Postoperative modified Glasgow prognostic score as an independent predictor of overall survival in clinically localized clear cell renal cell carcinoma. ( H15 )
Lindsey Allison Herrel - Emory University
Abstract # 457 : VHL protein (pVHL) and Src expression in metastatic RCC. ( H16 )
Kyle William Robinson - Oregon Health and Science University
Abstract # 458 : Are there geographic differences in the outcome of patients (pts) with metastatic renal cell carcinoma (mRCC) treated with sunitinib (su)? ( J1 )
Daniel Keizman - Genitourinary Oncology Service, Division of Oncology, Meir Medical Center, Sackler School of Medicine, Tel Aviv University
Abstract # 459 : Renal cell carcinoma: A prognostic target for spectral pathology. ( J2 )
Caryn S. Hughes - Manchester Institute of Biotechnology, The University of Manchestester
Abstract # 460 : Predicting survival in renal cell carcinoma: The role of quality-of-life assessment. ( J3 )
Digant Gupta - Cancer Treatment Centers of America
Abstract # 461 : Difference in adverse-event profiles between mTOR inhibitors, temsirolimus, and everolimus for advanced renal cell carcinoma. ( J4 )
Masahiro Nozawa - Department of Urology, Kinki University School of Medicine
Abstract # 462 : Treatment of adenocortical carcinoma: 11-year Birmingham experience. ( J5 )
Lenka Zvirinska - University Hospital Birmingham--Queen Elizabeth
Abstract # 463 : Involvement of miRNAs in the formation and maintenance of self-renewing kidney cancer spheres with stem cell properties. ( J6 )
Zsuzsanna Lichner - Li Ka Shing Knowledge Institute at St. Michael's Hospital
Abstract # 464 : Sunitinib (SU) plus extended courses of irradiated allogeneic lymphocytes (IAL) for patients with metastatic renal cell carcinoma (RCC). ( J7 )
Mark N. Stein - Cancer Institute of New Jersey
Abstract # 465 : Efficacy of sorafenib in advanced renal cell carcinoma (RCC) independent of prior treatment, histology, or prognostic group.^ ( J8 )
Ali Tafreshi - Joint Austin-Ludwig Oncology Unit, Austin Health
Abstract # 466 : Correlation of pathologic findings after brief neoadjuvant sorafenib with results of dynamic-contrast enhanced (DCE) and diffusion-weighted magnetic resonance imaging (DW-MRI) in patients with locally advanced or metastatic clear cell renal cell carcinoma (RCC). ( J9 )
Gary R. MacVicar - Feinberg School of Medicine, Northwestern University
Abstract # 467 : Classification of oncocytic papillary renal cell carcinoma. ( J10 )
Stephen Hembree Culp - University of Virginia
Abstract # 468 : Identification of biomarkers for overall survival of patients with metastatic renal cell carcinoma treated with MGN1601. ( J11 )
Viktor Grünwald - Department of Hematology, Hemostasis, Oncology, and Stem Cell Transplantation, Hannover Medical School
Abstract # 469 : Effect of novel growth hormone-releasing hormone antagonists on growth of experimental renal cell carcinomas. ( J12 )
Ferenc Rick - Miami VA Medical Center
Abstract # 470 : Prognostic factors and validation of prognostic nomograms in patients (pts) treated with three targeted therapies (TTs) for metastatic renal cell carcinoma (mRCC): Results from an Italian survey. ( J13 )
Roberto Iacovelli - Department of Radiology Oncology and Human Pathology, Oncology Unit, Sapienza University of Rome
Abstract # 471 : Fluorescence in situ hybridization (FISH) and array-comparative genomic hybridization (a-CGH) from percutaneous needle biopsy compared to renal mass histology. ( J14 )
Massimiliano Spaliviero - Department of Surgery, Sidney Kimmel Center for Prostate and Urologic Cancers, Memorial Sloan-Kettering Cancer Center, New York, NY
Abstract # 472 : Sarcomatoid renal cell carcinoma (SRCC): University of Nebraska Medical Center experience. ( K1 )
Pavankumar Tandra - University Of Nebraska Medical Center
Abstract # 473 : Defining heminephrectomy for cancer. ( K2 )
Joseph C. Klink - Glickman Urological & Kidney Institute, Cleveland Clinic
Abstract # 474 : Preoperative C-reactive protein does not improve predictive accuracy in clear cell renal cell carcinoma. ( K3 )
Stephan Kruck - Department of Urology, University Tuebingen
Abstract # 475 : Elevated pS6K levels in the sarcomatoid component of tumors derived from patients with metastatic renal cell carcinoma (mRCC). ( K4 )
Sumanta Kumar Pal - City of Hope
Abstract # 476 : Outcomes of sunitinib therapy in patients (pts) with metastatic renal cell carcinoma (mRCC) with poor risk features. ( K5 )
Romualdo Barroso-Sousa - Instituto do Câncer do Estado de São Paulo, Faculdade de Medicina da Universidade de São Paulo
Abstract # 477 : Outcomes of patients with metastatic renal cell cancer treated with sunitinib in clinical practice at a reference cancer centre in Manchester, United Kingdom. ( K6 )
Victoria Galvis - The Christie NHS Foundation Trust
Abstracts that were granted an exception in accordance with ASCO's Conflict of Interest Policy and are designated with a caret symbol (^) here and in the printed Proceedings.
